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Abstract 
A diet rich in fruits and vegetables has been associated with a decreased risk of brain diseases. 
Some plant-specific compounds occurring in fruits and vegetables, such as flavonoids, have 
been found to exert neuroprotection, thus decreasing neurological disease risk. The current 
hypothesis is that neuroprotection is due to the antioxidant properties of flavonoids.  
The main aims of this PhD thesis were: i) to assess whether some flavonoids are transported 
from the blood into the brain across the blood-brain barrier, ii) to understand if 
neuroprotection is mediated by an impact on brain metabolism.  
The first part of the thesis describes in vivo experiments with cyanidin 3-glucoside (C3G), 
implementing different metabolomics analyses approaches. Mean Time (MT) parameters are 
reported as useful indicators of the retention properties of C3G in peripheral tissues. The 
second part deals with the development and characterization of a selective and sensitive 
analytical method, based on Surface-Enhanced Raman Spectroscopy (SERS), enabling the 
assessment of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in living 
cells.  
 
Abstract 
Una dieta ricca in frutta e verdura è stata associata a un ridotto rischio di malattie 
neurodegenerative, e alcuni composti antiossidanti presenti in frutta e verdura, come i 
flavonoidi, sono stati riconosciuti come agenti neuroprotettivi. Gli obiettivi principali 
dell’attività di ricerca riportata in questa tesi sono stati la valutazione del passaggio dal sangue 
al cervello, attraverso la barriera emato-encefalica, di alcuni flavonoidi, la comprensione del 
loro impatto sul metabolismo del cervello e del loro meccanismo d'azione come agenti 
neuroprotettivi. La prima parte della tesi descrive diversi approcci di analisi metabolomica 
utilizzati in esperimenti in vivo con cianidina 3-glucoside (C3G). Parametri di tempo medio 
sono riportati come utili indicatori delle proprietà di ritenzione di C3G nei tessuti periferici.  
La seconda parte presenta lo sviluppo e la caratterizzazione di un metodo analitico, basato 
sulla spettroscopia Raman amplificata da superfici (SERS), per la determinazione di specie 
reattive dell’ossigeno e dell’azoto (ROS/RNS), in cellule viventi. 
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Abbreviation  Description 
A T0 intercept of distribution kinetics; dependent on dose and PK properties 
α Exponent of the polyexponential equation (slope factor) 
β Exponent of the polyexponential equation (slope factor) 
ABAP 2,2’-azobis (2-amidinopropane) dihydrochloride 
AIC Akaike’s information criteria 
AUC0-inf Area under curve out to infinity; 
AUMC  Area Under the first Moment Curve from time 0 to infinity  
AuNPs Gold nanoparticles 
B T0 intercept of elimination phase; dependent on dose and PK properties 
C(t)  Drug concentration at time t  
C0 Back-extrapolated drug concentration following rapid bolus iv 
administration  
C3G Cyanidin-3-glucoside 
CLd Distribution clearance; a measure of the ability of a drug to pass into and 
out of the tissues of the peripheral compartment. Constant of 
proportionality between rate of distribution and rate of redistribution 
CLT Total body clearance; a measure of the ability of the organs of elimination 
to remove drug from the plasma; proportionality constant between rate of 
elimination and plasma concentration 
Cmax  Maximum observed concentration  
Cmin  Minimum observed concentration over a dosing interval  
D3G Delphinidin-3-glucoside 
DCM Dichloromethane 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO Dimethylsulphoxide 
EMA  European Medicines Agency  
ESI Electrospray ionisation 
FBS Fetal bovine serum 
FCS Fetal calf serum 
FDA  Food and Drug Administration  
FDR False Discovery Rate 
GSH Glutathione (reduced form) 
GSSG Glutathione (oxidized form) 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC High performance liquid chromatography 
IC Number of circulations. Average number of times molecules return to the 
central compartment after passage through it. 
isoPN3G Iso-peonidin-3-glucoside 
Kp Measure of relative distribution of drug over the two compartments.  
k10 rate constant for elimination of drug from central compartment to outside 
body 
k12 rate constant for distribution of drug from central compartment to 
peripheral compartment 
k21 rate constant for redistribution of drug from peripheral to central 
compartment 
LC/MS Liquid chromatography mass spectrometry 
LTQ Linear trap quadrupole 
M3G malvidin-3-O-glucoside 
MPA 3-mercaptopropionic acid 
MRT Mean Residence Time; the average time spent in the body by a drug 
molecule 
MRTC Mean Residence Time in the central compartment 
MRTP Mean Residence Time in the peripheral space 
MTT Meat Transit Time; 
MTTi Mean Transit Time in a specific tissue i 
NCA  Non-Compartmental Analysis  
NPs Nanoparticles 
PBS Phosphate Buffered Saline 
PCA Principal component Analysis 
PG3G Pelargonidin-3-O-glucoside  
PK  Pharmacokinetic(s)  
PN3G peonidin-3-O-glucoside  
PT3G Petunidin-3-O-glucoside 
RNS Reactive Nitrogen Species 
ROS Reactive Oxygen Species 
RPMI Roswell Park Memorial Institute medium 
SC Schwartz criteria 
SERS Surface-enhanced Raman Scattering 
SPR Surface Plasmon Resonance 
t1/2 Terminal elimination half-life or apparent terminal elimination half-life, for 
compounds presenting release/absorption as limiting steps 
t1/2d Distribution half-life. Takes 1 t1/2 for distribution to go to 50% completion 
and 3-5 t1/2 for distribution to go to completion 
t1/2e Elimination half-life. Takes 1 t1/2 to eliminate 50% of dose and  3-5 t1/2 for 
elimination to go to completion 
TEM Transmission electron microscopy 
tlast  Time of Clast  
tmax  Time of occurrence of Cmax  
tmin  Time of occurrence of Cmin  
ToF Time-of-Flight 
Uv-vis Ultra violet-visible 
V1 Volume of central compartment; volume of distribution at T0; entire dose 
in V1 
V2 Volume of peripheral compartment 
  
Vss Volume of distribution at steady state following iv administration. At 
steady state rate of distribution equals rate of redistribution and volume of 
distribution = V1 + V2 
WSSR  Weighted sum of square of residuals 
Vz Apparent volume of distribution during terminal phase 
λz First order terminal elimination rate constant 
Synopsis 
A diet rich in fruits and vegetables has been associated with a decreased risk of brain diseases. 
Some plant-specific compounds occurring in fruits and vegetables, such as flavonoids, have 
been found to exert neuroprotection, thus decreasing neurological disease risk. The current 
hypothesis is that neuroprotection is due to the antioxidant properties of flavonoids.  
The main aims of this PhD thesis were: i) to assess whether some flavonoids are transported 
from the blood into the brain across the blood-brain barrier, ii) to understand if 
neuroprotection is mediated by an impact on brain metabolism.  
For the illustration of the above work, this PhD thesis has been divided in four sections.  
• Section I provides the theoretical background and a survey of the analytical 
techniques, instrumentation, and data processing techniques used. 
o Chapter 1 reviews the literature on the putative role of flavonoids as 
antioxidant agents in the contest of neurodegeneration and dementia-related 
diseases. Bioavailability and pharmacokinetic issues are discussed. 
o In chapter 2 various analytical approaches in metabolomics are reviewed. 
Specifically, attention is paid to common platforms and strategies to data 
acquisition, data pretreatment, preprocessing and multivariate analysis of 
metabolomics data. 
• Section II describes in vivo experiments implementing different metabolomics 
analyses approaches.  
o Chapter 4 presents the relationship between plasma C3G values and C3G 
amounts in the rat brain in the very early phase (i.e. 0-20 min) after C3G 
administration. Mean Time (MT) parameters are reported as useful indicators 
of the retention properties of C3G in peripheral tissues;  
o Chapter 5 discusses a method validation for an untargeted profiling of rat 
brain. 
• Section III deals with the development and characterization of a selective and sensitive 
analytical method, based on Surface-Enhanced Raman scattering (SERS) 
spectroscopy, enabling the assessment of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) in living cells.  
o Chapter 6 examines three possible novel nanosensors (NS) composed of 
oxidation-sensitive reporter molecules, adsorbed onto the surface of gold 
nanoparticles (Au-NPs). The rationale is that various ROS/RNS can induce a 
chemical change in the structure of the adsorbed molecules that is reflected in 
specific spectral differences, thus allowing measurement of specific ROS/RNS 
under versatile experimental conditions; 
o In Chapter 7 one SERS-based NS has been further refined for SERS-imaging 
technique with the ultimate goal to enable real-time intracellular observations 
in living cells.  
Conclusions and recommendations s for future work are discussed in Section IV. 
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Introduction 
The grand challenge of healthy ageing in the European Union 
One of the most recent documents on population aging released by the European Commission 
claims that “Europe is the oldest region in the world” (Marcowycz & Futurage Team, 2011). 
Population aging has been a policy priority at both the member state and European Union 
levels for more than two decades and in recent years has been promoted to the level of a 
“grand challenge”: the number of Europeans aged 65 and older is expected to increase by 
45% between 2008 and 2030 and will exceed 30% of the total population by 2060.  
Old age is characterized by an increased risk for multiple chronic diseases (e.g., hypertension, 
atherosclerosis, coronary syndromes, dementia-related disorders). Therefore, it is important to 
determine approaches that can be used today to promote healthy aging, forestall the onset of 
these chronic diseases, and create conditions favorable for obtaining a “longevity dividend” in 
both financial and human terms.  
Aside from the cardiovascular system, the brain is affected most significantly by the lifelong 
impact of stressors such as reactive oxygen and nitrogen species (ROS and RNS, respectively). 
Several cellular and molecular events are also thought to be related to oxidative stress, 
including impaired mitochondrial function, activation of neuronal apoptosis, deposition of 
aggregated proteins, and excitotoxicity. The majority of drug treatments for 
neurodegenerative disorders are ineffective, and consequently, there is an urgent need to 
develop alternative therapies for preventing the progressive loss of specific neuronal 
populations (Desai et al., 2010).  
As one of the most important lifestyle factors, diet can strongly influence the incidence and 
onset of neurodegenerative disorders. Epidemiological studies have demonstrated the positive 
effect of a fruit- and vegetable rich-diet on pathologies strictly linked with an imbalance in 
redox status, including aging, cancer, cardiovascular disease, and some degenerative diseases 
(Campbell et al., 1998; Jin et al., 2011). Detailed investigations into the specific dietary 
components of these foods have consistently suggested that a group of phytochemicals known 
as flavonoids is highly effective in reversing age-related declines in neurocognitive 
performance. In particular, foods rich in three specific flavonoid subgroups—flavanols, 
anthocyanins, and flavanones—seem to have the greatest potential to act on cognitive 
processes (Bohm et al., 1998). The consumption of flavonoid-rich foods and beverages 
reportedly limits the neurodegeneration associated with a variety of neurological disorders 
and prevents or reverses normal and abnormal deterioration in cognitive performance (Steele 
et al., 2007). 
In addition, a growing number of flavonoids have been shown to inhibit the development of 
Alzheimer’s disease (AD)-like pathology and reverse deficits in cognition. These effects 
suggest that flavonoids may have potential therapeutic utility in dementia-related disorders 
(Dragicevic et al., 2011; Spencer, 2008b). 
 
 
Diet and healthy ageing: State-of-the-art of the scientific knowledge 
Aging is associated with many common chronic neurodegenerative diseases; however, the 
precise cause of the neuronal degeneration underlying these diseases, and indeed normal brain 
aging, remains unclear (Desai et al., 2010). Because the neuropathology of many 
neurodegenerative diseases has been linked to increases in brain oxidative stress, strong 
efforts have historically been directed at exploring antioxidant strategies for combating 
neuronal damage. Recently, intense interest has developed in the potential of flavonoids—
anthocyanins in particular—to modulate neuronal function and prevent age-related 
neurodegeneration (Spencer, 2010). For example, red wine is a rich source of flavonoids 
(Mattivi et al., 2006), and its moderate consumption is associated with a decreased risk for 
cardiovascular (Dohadwala & Vita, 2009; Karatzi et al., 2009; Walzem, 2008) and 
neurodegenerative (Collins et al., 2009; Panza et al., 2009) diseases. 
Flavonoids may exert their positive effects via several mechanisms—e.g., (i) neuroprotection 
against neurotoxins (Spencer, 2008a), (ii) suppression of neuroinflammation (Vafeiadou et al., 
2007), and (iii) enhancement of the cellular pathways linked to memory, learning, and 
cognitive function (Spencer, 2008b, 2009, 2010). In recent years, the classic view of 
flavonoids as antioxidants via direct scavenging of ROS and RNS (Rice-Evans et al., 1996; 
Terao, 2009) has been replaced by a more realistic view that they act as modulators of key 
enzymes involved in metabolic and signaling pathways, thereby allowing fine control of 
endogenous ROS formation (Alvarez et al., 2010; Androutsopoulos et al., 2010; Chalopin et 
al., 2010; Gokara et al., 2010; Huang et al., 2010; Londono-Londono et al., 2010; Ochiai et al., 
2009; Ragazzon et al., 2009; Rashidi & Nazemiyeh, 2010; Sheng et al., 2009; Sirk et al., 
2009). Nonetheless, information about the capacity of flavonoids to pass through or interact 
with the blood–brain barrier is lacking (Faria et al., 2011), and our studies have attempted to 
address this gap. 
Together these observations make an even more urgent case for explaining the available 
epidemiological data, which thus encourages a better understanding of flavonoid bioactivity. 
In turn, such scientific knowledge is needed to provide human populations with sound 
guidelines for choosing diet and lifestyle. 
Some studies have succeeded in filling knowledge gaps concerning the rapid absorption of 
grape anthocyanins (wine pigments) in the stomach (Passamonti, Vrhovsek, Vanzo, et al., 
2003) and their fast distribution in tissues such as the brain (Passamonti et al., 2005), liver 
(Passamonti, Vrhovsek, Terdoslavich, et al., 2003), and kidneys (Vanzo et al., 2008). The 
amounts of anthocyanins recovered and measured in these tissues are very low, however—
i.e., too low to justify ROS scavenging—and thus suggest that their biological activities might 
be due to a highly specific interaction with the active sites of cellular enzymes, their 
regulation, or both. “Omics” approaches are undoubtedly the most suitable for obtaining a 
global view of the impact of anthocyanins on enzyme function (Fiehn, 2002; Kell, 2006; 
Weckwerth & Fiehn, 2002). However, the time window in which anthocyanins have peak 
impact on cells is very short (less than a few minutes). Therefore, the effects of anthocyanins 
are unlikely to be detected as changes at the transcriptome or proteome levels. Only changes 
at the metabolome level can reasonably be expected.  
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Neurodegeneration, brain pathology and dementia syndrome 
The Alzheimer’s Association (Prince et al., 2014) defines dementia as “a group of disorders 
that cause irreversible cognitive decline as a result of various biological mechanisms that 
damage brain cells.” This definition appropriately describes neurodegenerative disorders in 
general, in which neurons are lost due to biological malfunction. However, although many 
neurodegenerative conditions are recognized, there is no fine line that separates one from 
another (Ubhi et al., 2010). For instance, symptoms such as motor impairment, memory loss, 
hallucinations, and agitation may occur in several types of neurodegenerative disorders. No 
diagnostic biomarkers of dementia-related brain damage have been established (Frisoni et al., 
2013), and the mechanisms that link this damage to the expression of dementia symptoms are 
not fully understood (Savva et al., 2009). Thus, clinical diagnoses are usually based on 
qualitative evaluations of symptoms.  
Similar to the systemic changes in other chronic conditions such as cardiovascular disease and 
cancer, neuronal loss in neurodegenerative disorders begins decades before the onset of 
clinical symptoms, which may be a transition point in the accumulation of brain damage over 
time. Accordingly, the brain may have a certain “buffering” capacity that maintains 
acceptable cognitive function even during progressive pathological neurodegeneration 
(McDowell et al., 2007; Mortimer, 1997). 
The four most common subtypes of dementia-type disorders in order of frequency are AD, 
vascular dementia, Lewy body dementia, and frontotemporal dementia (Table 2.1). However, 
evidence from neuropathological studies challenges the notion of “one disease, one 
pathology”: mixed pathologies are much more common than “pure” ones (Langa et al., 2004; 
Neuropathology Group. Medical Research Council Cognitive & Aging, 2001; Schneider et 
al., 2007). The brains of individuals with one form of neurodegeneration can also have the 
pathological markers of another because two disorders may share risk factors as well as 
pathological events.  
Aging has been established as a major risk factor for neurodegenerative diseases, and 
neurodegeneration appears to accompany accelerated or dysfunctional aging (Prince et al., 
2014). Hypercholesterolemia, hypertension, atherosclerosis, coronary heart disease, smoking, 
obesity, and diabetes are also linked to the development of underlying neuropathologies 
because they are vascular risk factors that affect the effective supply of blood to the brain 
(Luchsinger & Mayeux, 2004; Shobab et al., 2005). Other risks factors include high intake of 
salt (Gandy & DeKosky, 2013) and of saturated and trans fats (Gillette Guyonnet et al., 
2007).  
On the contrary, evidence from cross-sectional studies suggests that compared with adults 
with dementia, older people with normal cognitive function tend to consume a healthier diet 
that is richer in fruits and vegetables and have a higher intake of homocysteine-related 
vitamins (vitamin B12 and folate), antioxidants such as flavonoids, and omega-3 poly-
unsaturated fatty acids (Blennow et al., 2006; Luchsinger & Mayeux, 2004). From this 
perspective, a growing consensus has emerged in recent years that dementia is preventable to 
some extent through the modification of environmental and behavioral factors (Standridge, 
2004). 
 
Oxidative stress and neurodegenerative disorders 
All neurodegenerative disorders, are characterized by the progressive atrophy of neurons. 
Although the mechanisms responsible for neuronal death remain to be completely elucidated, 
advances in systems biology have allowed our understanding of aging and neurodegeneration 
to accumulate. Many studies have suggested that a central biochemical feature of the 
implicated pathology of this atrophy is an unbalanced accumulation of oxidative stress linked 
to mitochondrial dysfunction (Folbergrova et al., 2012; Higgins et al., 2010; Moreira et al., 
2010; Nagley et al., 2010; Sims & Muyderman, 2010). Oxidative stress is a condition in 
which the balance between the production of intracellular small-molecule reactive species 
(Wang et al., 2012) and the level of endogenous antioxidants is significantly disturbed.  
Oxygen is essential for the normal function of eukaryotic organisms. Approximately 2% of 
the oxygen that enters living cells is converted into ROS and RNS amid a system of reactions 
that constantly consumes these species (Boveris et al., 1972). However, cells that produce 
reactive species at a greater rate than can be consumed by related intracellular systems enter a 
state of hyperoxia, which produces toxicities that include neurotoxicity (Ahdab-Barmada et 
al., 1986; Danilov & Fiskum, 2008; Hinkelbein et al., 2010). 
The toxicity and chemical reactivity of oxygen rely on its electronic structure. The identical 
electron spin states of its two outer-orbital electrons make oxygen kinetically stable except in 
the presence of catalysts that disturb these spin states to produce partially reduced forms of 
oxygen, mostly ROS and RNS (Valko et al., 2007). During cellular oxidative stress, free 
radical forms of ROS or RNS steal electrons from lipids, proteins, carbohydrates, or nucleic 
acids, thereby damaging these essential biomolecules. To protect cells from ROS/RNS-
induced oxidative insults, aerobic organisms have evolved an array of antioxidant defense 
systems: (i) enzymatic antioxidants (e.g., superoxide dismutase [SOD], catalase, peroxidases, 
and heme oxygenase), and (ii) non-enzymatic redox-regulating antioxidants (e.g., glutathione 
and vitamin C) (Droge, 2002).  
ROS/RNS toxicity is a primary pathogenic factor not only in neurodegenerative disorders 
such as AD, Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) (Gandhi & 
Abramov, 2012; Halliwell, 2006; Mhatre et al., 2004) but also in many non-degenerative 
brain diseases—e.g., cerebral stroke (Chen et al., 2011), epilepsy (Aguiar et al., 2012; Shin et 
al., 2011), hepatic encephalopathy (Skowronska & Albrecht, 2013), and brain dysfunction 
related to heavy metal toxicity (Farina et al., 2013).  
Increases in ROS concentrations in the brain seem not to be caused by elevations in oxidative 
stress but rather by a decline in antioxidant defense and repair mechanisms, thus resulting in 
the accumulation of oxidative damage (Aarsland et al., 2004). For instance, the activities of 
SOD, catalase, glutathione peroxidase, and glutathione reductase are reduced in the affected 
brain regions of AD patients (Pappolla et al., 1992; Zemlan et al., 1989). The amount of 
Figure 2.1 Main pathways of ROS/RNS formation. 
glutathione is also reduced in the substantia nigra of PD patients (Pearce et al., 1997). In 
addition, oxidative stress and other molecular mechanisms interact, which causes 
neurodegeneration such as protein misfolding. 
 
Table 2.1 Main reactive oxygen and nitrogen species 
Reactive Oxygen Species (ROS) 
Radicals  Non radicals  
Superoxide O2•−   Hydrogen Peroxide H2O2   
Hydroxyl HO•   Singlet Oxygene O2(1Δg )  
Peroxyl RO2•   
  
Alkoxyl RO•     
Hydroperoxyl HO2•   
  
Reactive Nitrogen Species (RNS) 
Radicals  Non radicals  
Nitrogen monoxide NO•   Nitrous acid HNO2   
Nitrogen dioxide NO2•   Nitrosyl cation NO+   
  Nitrosyl anion NO−  
  Peroxynitrite ONOO−   
 
Oxidative damage and protein conformational diseases 
AD, PD, Huntington’s disease, ALS, and Friedreich’s ataxia belong to a class of the protein 
conformational diseases that are characterized by the accumulation of disease-specific 
misfolded proteins in the central nervous system (Crunkhorn, 2012; Tabner et al., 2001; 
Zerovnik, 2010). Between 1906 and 1910, Alois Alzheimer and Gaetano Perusini first 
described a collection of dense deposits or plaques outside the neurons and bands of fibers or 
tangles within the autopsied brain cells of four people affected by an unknown type of 
dementia (Macchi et al., 1997). This disorder later became known as AD. The plaques were 
composed of amyloid beta peptides, and the tangles were tau/phosphorylated tau proteins. 
Other examples of plaques and fibers include alpha-synuclein in Lewy body dementia (van 
Ham et al., 2008), and mutant huntingtin in Huntington’s diseases (Scherzinger et al., 1997).  
Under normal conditions, cells use mechanisms such as the unfolded protein response for 
general balancing of protein delivery to the endoplasmic reticulum (ER) and protein folding 
(Zhang & Kaufman, 2006). Furthermore, if proteins are misfolded, the cellular response is 
either to (i) break up abnormal protein aggregates and facilitating protein refolding, or (ii) 
deliver misfolded proteins to the proteasome for recycling if they cannot be rescued by 
refolding (Zhang & Kaufman, 2006). Disorders associated with abnormalities in protein 
conformations arise from the dysfunctional misfolding of proteins in non-native 
conformations. One consequence of the formation of these intracellular abnormal protein 
aggregates is ER dysfunction (stress) that leads to mitochondrial dysfunction, excessive 
production of ROS, and oxidative stress. The capacity of cells to combat elevated levels of 
ROS (and RNS) involves the activation of pro-survival pathways as well as the production of 
molecules endowed with antioxidant and anti-apoptotic actions (Calabrese et al., 2009).  
Recent studies (de la Monte & Tong, 2014) have suggested that a localized, brain-specific, 
insulin/insulin-like growth factor resistance initiates a cascade driven by increased oxidative 
stress, neuroinflammation, impaired cell survival, mitochondrial dysfunction, dysregulated 
lipid metabolism, and ER stress. The cascade leads to neuronal dysfunction and death in AD. 
In this context, the molecular, biochemical, and degenerative features of AD correspond with 
the abnormalities that occur within the spectrum of systemic insulin resistance diseases.   
 Table 2.2.2 Abridged list of the most common type of dementia-related disorders. Modified from (Prince et al., 2014).  
Dementia subtype Early characteristic symptoms Neuropathology 
Proportion of 
dementia cases 
Alzheimer’s Disease 
(AD) 
Impaired memory, 
apathy and 
depression 
 
Gradual onset 
Cortical amyloid 
plaques and 
neurofibrillary tangles  
50-75% 
Vascular Dementia 
(VaD) 
Similar to AD, but 
memory less affected, 
and mood fluctuations 
more prominent 
 
Physical frailty  
 
Stepwise onset 
Cerebrovascular 
disease  
Single infarcts in 
critical regions, or 
more diffuse multi-
infarct disease  
20-30% 
Lewy Bodies 
Dementia (LBD)* 
Marked fluctuation in 
cognitive ability 
 
Visual hallucinations  
 
Parkinsonism (tremor 
ad rigidity) 
Cortical Lewy bodies 
(alpha-synuclein)  <5% 
Frontotemporal 
dementia  
Personality changes 
 
Mood changes 
 
Disinhibition 
 
Language difficulties 
No single pathology – 
damage limited to 
frontal and temporal 
lobes  
5-10% 
Creutzfeldt-Jakob 
disease 
Rapidly fatal disorder 
that impairs memory 
and coordination and 
causes behavior 
changes. 
Prion proteins <5% 
* Lewy body dementia (LBD) is not a single disorder but a spectrum of disorders including Parkinson's Disease 
Dementia (PDD) and Dementia with Lewy Bodies (DLB). Because DLB and PDD share many clinical and 
pathological characteristics, both are classified as forms of LBD.  
Flavonoids as neuroprotectors 
 
Antioxidants 
The term antioxidant refers to any substance that, present at a low concentration compared 
with that of an oxidizable substrate, significantly delays or prevents the oxidation of that 
substrate (Halliwell, 1999). Antioxidants are thought to act against neurodegeneration by 
limiting the production of toxic substances and reducing damage by free radicals (Mao, 
2013). There are relatively fewer antioxidant enzymes specifically focused on neuronal 
protection, suggesting that antioxidant nutrients may have a more prominent role in older and 
aging brains than in other organ systems (Olanow, 1990).  
Numerous epidemiologic studies have shown an inverse correlation between dietary flavonoid 
consumption and age-dependent cognitive decline and dementia, including AD and PD 
(Commenges et al., 2000; de Rijk et al., 1997; Orgogozo et al., 1997). Emerging evidence 
suggests that dietary-derived flavonoids have the potential to improve human memory and 
neurocognitive performance via their capacity to protect vulnerable neurons, enhance existing 
neuronal function, and stimulate neuronal regeneration (Gutierrez-Merino et al., 2011; J. P. 
Spencer, 2009). A clinical study demonstrated that 12 weeks of dietary supplementation with 
grape juice may have neurocognitive benefits in older adults with early memory decline (R. 
Krikorian et al., 2010) and can improve memory functions in older adults with mild memory 
decline (Robert Krikorian et al., 2012). In addition, flavonoids have been shown to target the 
complex general mechanisms of neurodegenerative diseases in various cell cultures and 
animal models (Basli et al., 2012; Dajas et al., 2003; Echeverry et al., 2010; Zhu et al., 2007). 
However, clinical trials of flavonoid dietary supplementation or novel dosage forms based on 
red wine extract remain scarce (Albarracin et al., 2012). 
The beneficial effects of these compounds have traditionally been attributed mainly to their 
antioxidant capacity in terms of radical scavenging properties of superoxide anions and 
hydroxyl and peroxy radicals (Nijveldt et al., 2001; Robak & Gryglewski, 1988). However, 
these actions seem to be mediated by the direct interactions of flavonoids and their 
metabolites with a number of cellular and molecular targets of crucial importance in 
controlling neuronal resistance to neurotoxins (Granzotto & Zatta, 2014; Zhu et al., 2007), 
ROS/RNS production (Calabrese et al., 2012), inflammatory mediators (Kao et al., 2010; 
Spilsbury et al., 2012), neuronal differentiation, long-term potentiation, and memory (J. P. E. 
Spencer, 2008). Antioxidants stimulate endogenous antioxidant enzymes (Steffen et al., 2008) 
while inhibiting xanthine oxidase and nicotinamide adenine dinucleotide phosphate oxidase, 
two major enzymes that generate large amounts of ROS (Nijveldt et al., 2001; Steffen et al., 
2008).  
From a chemical point of view, flavonoids are C15 compounds with C6–C3–C6 carbon 
frameworks—i.e., two benzene rings (A and B rings) are linked together by a group of three 
carbons (C ring), as shown in Figure 2.1. The main classes of flavonoids differ in oxidation 
levels and substitution patterns on the C ring, whereas individual compounds within a class 
differ in their substitution patterns on the A and B rings (Crozier et al., 2009). In general, 
flavonoids are classified according to their chemical structures, as shown in Table 2.2: (i) 
flavonols, (ii) flavones, (iii) flavanones, (iv) flavan-3-ols, (v) anthocyanidins, and (vi) 
isoflavones. 
 
Figure 2.2 Basic structural formula of a flavonoid. 
Anthocyanins 
Anthocyanins are glycosylated anthocyanidins, a subclass of flavonoids, that are found in 
plant tissue and display a great color diversity that touches nearly all visible spectra from 
orange and red to purple and blue (Del Rio et al., 2010; Kahkonen & Heinonen, 2003; Mazza, 
1993; Waterhouse, 2002).  
These compounds comprise one of the most widespread families of water-soluble pigments in 
the plant kingdom. As of 2013, the number of identified anthocyanins in nature was 702, and 
approximately 200 additional structures were proposed as tentative (Andersen & Jordheim, 
2013). The six anthocyanidins commonly found in the edible parts of plants are cyanidin 
(50%), pelargonidin (12%), peonidin (12%), delphinidin (12%), petunidin (7%), and malvidin 
(7%) (Kong et al., 2003), and they are classified according to the number and position of 
hydroxyl and methoxyl groups on the flavan nucleus—i.e., depending on the chemical groups 
in R1 and R3 (Figure 2.2)  
The anthocyanins consist of an aglycone (anthocyanidin), sugar(s), and in many cases, acyl 
group(s) and can thus be considered water-soluble glycosides of anthocyanidins. 
Anthocyanins are positively charged at acidic pH, and this equilibrium form is called 
flavylium cation (2-phenylbenzopyrylium). Although there are approximately 30 
anthocyanidins, 90% of all anthocyanins are based on the six most common anthocyanidins 
listed above, which differ only in the hydroxylation and methoxylation patterns on their B 
rings (Figures 2.2 and 2.3).  
Figure 2.3 Visible color range of common anthocyanidins (Ananga et al., 2013). 
The most common glycoside is 3-glycoside. If a second sugar is present, it is almost always a 
glucose residue at the 5-hydroxyl position. Such compounds are called 3,5-dimonosides. The 
most common sugar is glucose (90%), followed by rhamnose, galactose, xylose, and 
arabinose (Andersen & Markham, 2006). The anthocyanins can also be acylated; indeed, 
approximately 65% of reported anthocyanins with properly identified structures are acylated. 
The nature, number, and linkage positions of the acyl groups contribute substantially to 
anthocyanin diversity. Furthermore, the sugar units of anthocyanins may be acylated with 
aliphatic acyl groups, aromatic acyl groups, or both. The aromatic acyl groups include various 
hydroxycinnamic acids (p-coumaric, caffeic, ferulic, sinapic, and 3,5-dihydroxycinnamic 
acids) and two hydroxybenzoic acids (p-hydroxybenzoic and gallic acids). The aliphatic acyl 
group includes malonic acid (which is the most frequent aliphatic acyl group), and acetic, 
malic, succinic, tartaric, and oxalic acids (Andersen & Markham, 2006). 
 
Cyanidin-3-O-β-glucoside (C3G) has recently gained attention for its multifunctional 
neuroprotective effects, including protection against amyloid-beta-peptide-induced toxicity 
(Tarozzi et al., 2007; Tarozzi et al., 2010), antioxidant and cognitive promotion (Im et al., 
2013; Shih et al., 2010), and anti-ischemic and anti-inflammatory activity (Di Giacomo et al., 
2012; Kang et al., 2006). Indeed, chronic consumption of anthocyanins has been correlated 
with decreased incidence of age-associated cognitive decline and neurodegeneration (Gao et 
al., 2012; Robert Krikorian et al., 2012).  
Figure 2.4 Structures of common anthocyanidins. 
Another proposed mechanism of C3G neuroprotection involves effects on the vascular 
system—specifically, the capacity to increase brain blood flow and thus initiate neurogenesis 
in the hippocampus (Williams & Spencer, 2012). Recent in vitro studies have suggested that 
short-term C3G incubation (20 min) can activate signaling pathways related to 
neuroprotection—e.g., protection against ethanol-induced neuronal apoptosis in hippocampal 
neurons (Ali Shah et al., 2013). Importantly, C3G accumulates within brain endothelial cells 
(Milbury & Kalt, 2010) and has been shown to cross a blood–brain barrier cellular model in a 
time-dependent manner, in 1 hour (Faria et al., 2010). 
 
The biggest pharmacological concern of anthocyanins is their limited bioavailability, which 
results in very low plasma concentrations (0.1–1 μM) (Manach et al., 2005). These low 
concentrations are attributed to their poor absorption into the circulatory system from the 
small intestine and extensive cellular uptake into excretory organs (Vanzo et al., 2011) 
followed by fast and extensive metabolism. New insights into the complex metabolism of 
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Figure 2.5 Signaling pathway involved in the cognitive benefit of anthocyanins. Polyphenols activate eRK- cReB 
pathway and Akt- FOXO cascade leading to changes in synaptic strength and communication, and in angiogenesis 
through the activation of eNOS. On the other hand, anthocyanins are known to inhibit neuroinflammation through 
modulation of iNOS and COX-2, leading to a decrease in inflammatory markers. Altogether these effects enhance 
cognition and prevent neurodegeneration.  
anthocyanins have been obtained through recent feeding studies with human volunteers who 
ingested 0.5 g (1114 μmol) of 13C5-labelled C3G. After 48 hours, the relative bioavailability 
of C3G was 12% of the dose, with 5.4% excreted in urine, 6.9% in breath, and fecal excretion 
accounting for an additional 32%. These results suggested that anthocyanins have greater 
bioavailability than that previously reported (Czank et al., 2013). The maximum concentration 
of anthocyanin-derived circulating metabolites varied between 11 nmol/L for 4-
hydroxybenzoic acid-3-O-glucuronide (protocatechuic acid-3-O-glucuronide) and 1962 
nmol/L for hippuric acid (de Ferrars et al., 2014). The accumulation of multiple metabolites 
might ultimately be responsible for the reported bioactivity of anthocyanins, with gut 
microflora apparently playing key roles in the biotransformation process. 
Anthocyanins exhibit wide body distribution, as evidenced by their presence in various 
peripheral tissues. In particular, they are detected in the cortex and cerebellum of pigs fed a 
blueberry-supplemented diet for 4 weeks (Kalt et al., 2008). A similar study of oral 
administration in rats confirmed the presence of pelargonidin in the brain (el Mohsen et al., 
2006). Moreover, an experiment in rats with ligated stomachs showed that anthocyanins were 
present in brain tissue after even a short incubation (10 min) in the stomach (Passamonti et al., 
2005). The mechanisms remain to be elucidated, but the results of these studies suggest that 
anthocyanins accumulate in the central nervous system. 
 
Bioavailability and Pharmacokinetic Issues 
Flavonoids are highly bioactive, and have low apparent toxicity, which makes their medicinal 
use very attractive. Low plasma concentrations are attributed to their poor absorption and 
extensive cellular uptake into excretory organs (Vanzo et al., 2011) followed by metabolism.  
Tight regulation of flavonoid plasma concentration is accomplished by an additional 
mechanism, i.e. binding to serum albumin (Dufour & Dangles, 2005), which lowers plasma 
concentrations of unbound bioactive flavonoids, while offering a storing system for delayed 
release into the plasma. In addition, albumin-bound flavonoids are more stable against 
oxygen-dependent degradation (Kitson, 2004) so prolonging their biological availability and 
further extending their plasma half-life. These conditions would protect target tissues from a 
transient, spiking uptake of flavonoids, which might be trigger a toxic reaction of cells. 
Indeed, prolonged release of flavonoids form plasma proteins would determine a more 
constant rate of cellular uptake of flavonoids. 
However, low bioavailability must not be correlated with low bioactivity. Recent studies 
suggest that also some of the flavonoid metabolites have potential to posses similar 
pharmacodynamics as the parent compound (Terao et al., 2011). Moreover, a given flavonoid 
with its metabolites could have opposite, additive, or synergistic effects; therefore, the 
observed bioactivity in in vivo settings depends on the particular phenolic profile. Synergistic 
bioactivity of multiple flavonoids, as found in food matrices, is also important. For instance, 
the antiproliferative activity in vascular smooth muscle cells of four red wine polyphenols, i.e. 
resveratrol, quercetin, ethyl gallate, and (+)-catechin, was stronger than predicted additive 
activity of each individual substance (Kurin et al., 2012). In addition, also in anti-cancer 
research, two flavonoids, diosmetin and luteolin, exert synergistic cytostatic effects 
(Androutsopoulos & Spandidos, 2013). Synergistic pharmacodynamics has been also 
observed for flavonoids and drugs, e.g. the antiviral actions of acyclovir were potentiated by 
the 4'-phenylflavone (Hayashi et al., 2012). In general, there are numerous other studies 
confirming the synergy potential of flavonoids. This suggests an explanation for some of the 
epidemiological observations related to the fact that dietary flavonoids, even if present in low 
concentrations (nM range) in plasma, display health-protective properties. On the other hand, 
this brings about problems for in vitro cell-based assays or in situ isolated organ studies, 
which must focus not only on using single molecules or mixture of molecules (plant extract), 
but importantly also on the mixture of all their metabolites, and in physiologically relevant 
concentration range (nM-µM). 
 
Another important pharmacological concept, i.e. hormesis, must be introduced at this point in 
order to further explain the paradox of low bioavailability, but high bioactivity of flavonoids. 
Hormetic dose response is characterized by a biphasic dose-response, e.g. low-dose 
stimulation and a high-dose inhibition, or vice versa, and can result from either a direct 
stimulation or through an overcompensation stimulatory response following disruption in 
homeostasis (Calabrese et al., 2011). Flavonoids also exhibit hormesis, what can be 
represented with an example of quercetin bioactivity on cell-based studies. Cancer preventive 
effects of quercetin are observed at low concentrations of approximately 1-40 µM, and are 
likely to be mediated by quercetin’s antioxidant properties, while pro-oxidant cytotoxic 
effects are present at concentrations of 40-100 µM (Vargas & Burd, 2010). Flavonoids can be 
seen, in this context, as noxious molecules that reach subtoxic levels in human bodies, and 
thus induce mild cellular stress responses, which can involve activation of various kinases and 
transcription factors that induce the expression of genes that encode antioxidant enzymes, 
protein chaperones, metabolic phase-II enzymes, neurotropic factors, and other cytoprotective 
proteins (Son et al., 2008). 
 
Moreover, low concentrations of flavonoids (in physiological range) can affect the expression 
of genes involved in vascular aging. For instance, treatment of cultured human umbilical vein 
endothelial cells (HUVEC) with ferulic acid, quercetin or resveratrol (in 0.1 µM 
concentration) resulted in down-regulation (>2-fold) of 363 genes and up-regulation (>2-fold) 
of 233 genes, out of 10.000 analyzed genes (Nicholson et al., 2008). Importantly, the 
mentioned compounds significantly increased the expression of the gene encoding endothelial 
NO synthase (eNOS), while decreased expression of the potent vasoconstrictor endothelin-1 
(Nicholson et al., 2008). To further develop this concept, further research is needed to identify 
the cellular targets of flavonoids that account for cytoprotection (Mastaloudis & Wood, 2012), 
and not those who have in vitro antioxidant activity. For example, EGCG, via activation of 
Akt and ERK1/2 signaling pathway, upregulates heme oxygense-1 expression in endothelial 
cells (Wu et al., 2006) what leads to protection against oxidative stress (Wu et al., 2006). 
However, future research must answer whether activation of signaling pathways is triggered 
by binding of flavonoids to the cell membrane receptors or by binding to the intracellular 
targets following trans-membrane transport.  
 
To accurately translate observations from in vitro assays to in vivo studies, and even further to 
clinical studies, we must properly address the principal underlying mechanisms, which start 
by mechanistic interpretation of pharmacokinetic studies. 
Table 2.2 Pharmacokinetic properties of different flavonoid subclasses, as reported in the literature on animal and human studies. 
 
Flavonoid subclass Structure Pre-clinical pharmacokinetics 
Animal studies 
Clinical pharmacokinetics 
Human studies 
 
Anthocyanidins 
 
(Note: anthocyanins 
(AC) are glycosylated 
form) 
 
 
cmax (monomeric AC) = 0.18 µM [1] - 0.84 
µM[2] 
cmax (mixture, total AC) = 0.1 µM[3] – 3.8 
µM[4] 
tmax = 15 min[5] – 60 min[6]  
t1/2 = NRa 
BA = 0.49 %[2] – 1.82 %[5] 
 
 
cmax (monomeric AC) = 0.56 nM[7] – 5.8 nM[8] 
cmax (mixture, total AC) = 30 nM[6] – 0.5 µM[9] 
tmax= 0.5 h[10] – 2.2 h[11] 
t1/2 =1.5 h[10] – 6.6 h[11] 
 
Flavonols 
 
 
cmax= 0.9 µM[12] – 6.8 µM[13] 
tmax = 30 min [14] – 2.9 h [15] 
t1/2 =14.8 h[15] – 65.4 h[15] 
BA = 0.5% [16] – 5.3 %[17] 
 
 
cmax = 137 nM [18] – 7.64 µM [19] 
tmax = 0.68 h [19] – 7.5 h [18] 
t1/2 = 2.6 h [20] – 28.1 h [21] 
 
Flavones 
 
 
Cmax= 134 nM [22] - 50 µM [23] 
tmax = 15 min [24] –3.9 h [23] 
t1/2 = 0.8h [25] – 91.8 h[26] 
BA = 2.2 % [27] 
 
cmax= 127 nM[28] – 300 nM [29]  
tmax = 0.5h[30] - 7.2h[28] 
t1/2 = 3.1 h [29] 
 
Flavanones 
 
 
 
 
Cmax= 21 nM [31] – 6 µM [32] 
tmax = 20 [31] – 80 min [31] 
t1/2 =1.3 [32] – 2.2 h [32] 
BA = NRa  
 
 
Cmax= 60 nM[33] – 7.4 µM [34] 
tmax = 2 h [35] – 5.8 h[33]  
t1/2 = 1.3 h [32] – 3.1 h [34] 
 
Flavan-3-ols 
(Synonym: catechins) 
 
 
Cmax= 0.3 µM[36] – 2.7 µM [36] 
tmax = 24h[37] 
t1/2 = 41 min[38] – 4.03 h[36]  
BA = 0.1% [38] – 31.2% [38] 
 
 
Cmax= 70 nM[39] – 7.35 µM[40] 
tmax = 1.2h[39] – 4.1h[41] 
t1/2 = 0.42 h[42] –5.7 h [43] 
 
Isoflavones 
(Synonym: 
phytoestrogens) 
 
 
 
 
 
Cmax (rats)= 2.2 µM[44]– 20.9 µM[45] 
Cmax (cats)= 5 µM[46] – 15 µM[46]  
tmax = 10 min[45]  – 1.5h[46] 
t1/2 =8.5 h[44] – 17 h[47] 
BA = 1.4 %[47] – 30%[47] 
 
Cmax= 0.17 µM[48] – 25.4 µM[49] 
tmax = 2.5h[49] – 11h[49] 
t1/2 = 3.4h[50] – 10.8h[51] 
 
a BA, estimated oral bioavailability; cmax, maximal plasma concentration (peak) after single dose oral ingestion; tmax, time needed to reach cmax; 
t1/2, elimination half-life; NR – not reported in the literature. 
b detailed interactions between membrane transporters and specific flavonoids are presented in Table 1, with the corresponding references. 
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Chapter  3. Review of Analytical 
Techniques 
 
Nanotechnology, which is the creation of functional materials, devices, and systems through 
the control of nanoscale materials (Wang, 2005), has recently become one of the most 
influential fields at the forefront of systems biology, in which it plays a critical role in the 
discovery and validation of biomarkers by providing access to a wealth of information 
delivered by omics technologies (Sakamoto et al., 2010).  
In systems biology, omics technology components have the potential to be used for early 
detection of disease, to predict patient response to therapy, and to identify biomarkers (Kell, 
2006). This field is still evolving, but strong evidence in the scientific literature supports the 
role of nanotechnology as an empowering contributor that provides access to previously 
inaccessible data with excellent proficiency and resolution. 
 
Metabolomics 
Within the last decade, metabolomics has attracted great interest primarily in the search for 
disease biomarkers. Small molecules in a biological system can provide a wealth of 
information about overall functionality and perturbations within pathways and cycles of 
whole biological systems or selected cells, tissue, or organs (Fiehn, 2002).  
The term metabonomics was first formulated by the Nicholson group in 1999 to describe “the 
multiparametric, quantitative study of dynamic metabolome responses in living systems to 
physiological and pathophysiological stimulation or genetic modification” (Nicholson et al., 
1999). In 2001, a competing term, metabolomics, was proposed and generally defined as the 
“comprehensive and quantitative analysis of all metabolites” (Fiehn, 2002). Because the two 
terms are increasingly used interchangeably, this thesis uses metabolomics to encompass the 
definition of both words. 
The metabolome is the complete set of an organism’s metabolites. It represents a vast number 
of components that belong to a wide variety of classes. Metabolites are small intra- and 
extracellular molecules (smaller than 1.5 kDa) that act as carriers, substrates, or intermediate 
products in cellular biochemical pathways and reflect the upstream activities of genes and 
proteins. Common examples of metabolites are amino acids, lipids, organic acids, nucleotides, 
and vitamins, although inorganic and reactive species are also studied (Kell, 2007; Lahner et 
al., 2003). These compounds differ in their physical and chemical properties and occur in 
wide concentration ranges. Metabolites occur further down the line from genes or proteins to 
functions (the end products of cellular regulatory processes), and are therefore most closely 
related (compared with genes and proteins) to the activities of biological systems at the 
functional level. Therefore, metabolites are sensitive probes for homeostasis and its regulation 
(Goodacre, 2004, 2005).  
Metabolites are also modulated by several factors unrelated to the genome and reflect, for 
example, interactions with commensal microorganisms and modifications caused by nutrition 
or exposure to drugs and pollutants. Diseases, toxic insults, and other pathophysiological 
stimuli are expected to interfere with metabolism, consequently causing biochemical changes 
that can be captured as metabolic profiles or signatures. 
In contrast to transcriptional analysis, metabolomics does not necessitate a sequenced 
genome, and results are readily transferable from one species to another because metabolic 
detoxification pathways remain relatively well conserved. Another strength of metabolomics 
approaches is the possibility of collecting and integrating data from different compartments of 
the same organism—for example, biofluids such as urine or blood and tissues from specific 
organs. For these reasons, metabolomics has been increasingly recognized as a valuable tool 
in fields ranging from toxicology to plant physiology to biomedical research. 
Figure 3.1 Metabolomics is more time sensitive than other “omics”. 
Metabolomics is not without its challenges, however. Currently, no single analytical 
technique provides a comprehensive view of all of the metabolites present in a sample 
(Dettmer et al., 2007; Schiavo et al., 2008). Nevertheless, a number of integrated approaches 
have been developed to overcome the limitations of current technologies (Crockford et al., 
2006; Lenz & Wilson, 2007). 
 
Types of analyses 
Metabolomics analyses consist of a sequence of steps that include sample preparation, 
metabolite extraction, derivatization, metabolite separation, detection, and data treatment. In 
general, metabolomics analyses have been classified as targeted or untargeted.  
 
Targeted metabolomics is commonly driven by a specific biochemical question or 
hypothesis that motivates the investigation of a specific group of intended metabolites or one 
or more related metabolic pathways (Pereira et al., 2010; Ramautar et al., 2008). Targeted or 
metabolite-specific methods include the following: 
• Metabolite profiling  
 Metabolic profiling is the analysis of a group of metabolites related to either a specific 
metabolic pathway or a class of compounds. Some metabolites have been so widely 
studied that new nomenclatures have recently appeared—in lipidomics, for example, 
which assesses qualitative and quantitative information about the constitution of the 
cellular lipidome (a subcompartment of the metabolome comprising lipid classes, 
subclasses, and signaling molecules) and provides insights into the biochemical 
mechanisms of lipid metabolism and lipid–lipid and lipid–protein interactions 
(Griffiths & Wang, 2009). Metabolite profiling uses hyphenated techniques such as 
gas chromatography–mass spectrometry, liquid chromatography–mass spectrometry 
(LC/MS), and capillary electrophoresis–mass spectrometry. These techniques provide 
detailed chromatographic profiles of samples and measurements of the relative or 
absolute amounts of the components therein.  
• Target metabolite analysis  
 A more direct approach, target metabolite analysis measures selected analytes, such as 
biomarkers of disease or toxicant exposure or substrates and products of enzymatic 
reactions (Fiehn, 2002). Based on the aim of a study, metabolites are selected for 
analysis and specific analytical methods are developed for their determination 
(Dettmer et al., 2007). The analysis of C3G and its methylated derivatives with high-
performance liquid chromatography (HPLC)–mass spectrometry and pharmacokinetic 
characterization presented in Chapter 4 is an example of target metabolite analysis.  
• Metabolic fingerprinting  
Metabolic fingerprinting techniques involve the collection of spectra of unpurified 
solvent extracts under standardized conditions. These approaches initially ignore the 
assignment of individual peaks, which are frequently overlapping. Multivariate 
statistical methods such as principal component analysis (PCA) are used to compare 
sets of spectra to identify clusters of similarity or difference on which to draw 
conclusions about the classification of individual samples. The identities of 
metabolites responsible for differences between classes can be investigated from 
loading plots generated with PCA and related techniques (Ward et al., 2007). As such, 
only peaks that differ between samples are analyzed, thereby avoiding the time-
consuming task of identifying all peaks. Nuclear magnetic resonance spectroscopy, 
Raman spectroscopy, and Fourier-transform infrared spectroscopy are referred to as 
“fingerprinting” methods. They are more rapid, general screening methods that can be 
configured for high throughput and are suitable for determining differences and 
classifying samples (Halket et al., 2005). An example can be found in the development 
of a new method based on surface-enhanced Raman spectroscopy (SERS) presented in 
Chapter 7. 
These targeted approaches and practical aspects of quantitative metabolomics are discussed in 
detail elsewhere (Xu et al., 2009). 
 
By comparison, untargeted metabolomics approaches are global in scope, usually 
hypothesis free, and focus on the detection, identification, and quantitation of as many 
metabolites as analytically possible in biological samples. These approaches search for 
variations that can be used to obtain patterns or fingerprints that discriminate comparative 
samples (Monton & Soga, 2007). Because untargeted metabolomics requires no prior 
knowledge, it can be used to identify novel metabolic biomarkers of disease and drug 
efficacy. In the case of samples obtained from rats treated with or without C3G (see Chapter 
5), the aim was to identify treatment-related differences in one or more of the numerous 
endogenous metabolites found in the brain.  
Computational and mathematical models are then used to facilitate data processing and 
comparative analysis of metabolomics data subsets either for signature validation or 
biomarker identification.  
Metabolomics Workflow 
 
Figure 3.2 graphically represents the metabolomics workflow that starts with a biological 
question, including the design of experiments and data collection and analysis, and ends with 
the biological interpretation of results. Figure 3.1 also includes examples of the actions and 
tools used in this thesis. In this chapter, we describe strategies and methodology for data 
processing and statistical analysis, which are key factors in the metabolomics workflow.  
 
Figure 3.2 Metabolomic workflow. 
Statistical analyses  
Several data analyses and pattern-recognition algorithms are used to interpret the complex 
metabolic information obtained from experimental measurements and connect it to distinct 
biological phenomena. Statistical data analysis methods may include univariate/multivariate 
and unsupervised/supervised methods (Goodacre, 2005). 
 
Univariate methods 
Univariate methods are central to metabolomics. Typically, statistical hypothesis tests, such as 
a t-test or analysis of variance (ANOVA), are used to confirm significant differences between 
means. A key issue in statistical hypothesis testing is the increased risk of committing a type I 
error (incorrectly rejecting a null hypothesis): when comparing a large number of samples 
with hundreds of features, a significance threshold of p < 0.05 is insufficient (Broadhurst & 
Kell, 2006). There is a high probability that features identified as significant at p < 0.05 are 
not truly significant. A simple Bonferroni (Broadhurst & Kell, 2006) or the alternative and 
less stringent false discovery rate (FDR) (Benjamini & Hochberg, 1995) can be used to 
reduce the possibility of false discoveries. An FDR-adjusted p value (also called the q value) 
of 0.05 implies that 5% of significant tests will result in false positives. 
 
Multivariate methods 
The term chemometrics was coined by Svante Wold and Bruce R. Kowalski in the early 
1970s and is defined as the application of mathematical, statistical, graphical, or symbolic 
methods to extract information from complex biological and chemical systems for the 
selection of optimal experimental procedures and data treatments for analysis (Eriksson et al., 
2004; Wold, 1991) Since its introduction, chemometrics has grown into a well-established 
data analysis tool applied to various fields of chemistry, especially analytical chemistry, in 
areas such as multivariate calibration, quantitative structure–activity modeling, pattern 
recognition, and multivariate statistical process monitoring and control (Trygg et al., 2007).  
Metabolomics studies generate large and complex multivariate datasets. Therefore, 
chemometrics has become an integral part of global profiling and fingerprinting because it 
provides interpretable models for complex intercorrelated data and tools for making good use 
of measured data and devising quantitative models and visual representations of information. 
However, metabolomic datasets require several data preprocessing steps before multivariate 
analysis to achieve optimal characterization of the samples and generate reliable, interpretable 
models using multivariate analysis techniques.  
 
Preprocessing 
During preprocessing, data variables are centered and scaled with methods that are chosen 
based on the instrumental technique used (van den Berg et al., 2006). Normalization methods 
reduce the variance between samples through normalization to a constant sum, constant 
feature (e.g., an internal standard), or reference sample. Autoscaling (subtraction of the mean 
from each value within columns and dividing by the standard deviation) and Pareto scaling 
(the same process as autoscaling but dividing by the square root of the standard deviation) are 
common scaling methods used to reduce variance between the variables in metabolomics 
datasets. However, many other approaches, such as logarithmic or exponential scaling, are 
available (Broadhurst & Kell, 2006; Hendriks et al., 2011; van den Berg et al., 2006). Some of 
most common methods are listed in Table 3.1. 
After preprocessing, the use of multivariate statistical methods is critical for identifying 
statistically significant differences within large sets of information-rich chemical and 
biological data. The most common of these methods are listed in Table 3.2. Two general types 
of pattern recognition algorithms are used in multivariate statistical analyses: unsupervised 
and supervised (Worley & Powers, 2013). 
 
Table 3.1 List of most commonly used data scaling methods in multivariate analyses. 
Method Equation Goal Advantage Disadvantage 
Centering  !xik = xik − xk  
Focus on 
differences, not 
similarities 
Removes offset 
from the data 
Unsuitable for 
heteroscedastic 
data 
Auto 
scaling  
!xik =
xik − xk
sk
 
Compare 
metabolites based 
on correlation 
All metabolites 
equally important 
Inflation of 
measurement 
errors 
Range 
scaling  
!xik =
xik − xk
xk ,max − xk ,min
 
Compare 
metabolites relative 
to biological 
response range 
All metabolites 
equally important. 
Biologically related 
scaling 
Inflation of 
measurement 
errors, sensitive 
to outliers 
Pareto 
scaling  
!xik =
xik − xk
sk
 
Reduce relative 
importance of large 
values, partially 
preserve data 
structure 
Stays closer to 
original 
measurement than 
UV 
Sensitive to 
large fold 
changes 
Vast 
scaling  
!xik =
xik − xk
sk
⋅ xksk
 Focus on small 
fluctuations 
Aims for 
robustness, uses 
prior group 
knowledge 
Not suited for 
large induced 
variation 
without group 
structure 
Level 
scaling  
!xik =
xik − xk
xk
 Focus on relative 
response 
Suited for 
biomarker 
identification 
Inflation of 
measurements 
errors 
Log  
scaling  
!xik = log(xik )
x 'ik = !xik − xk
 
Correct for 
heteroscedasticity, 
pseudo scaling. 
Make 
multiplicative 
models additive  
Reduce 
heteroscedasticity, 
multiplicative 
effects become 
additive 
Difficulties 
with values 
with large 
relative 
standard 
deviation and 
zeros 
X is a data matrix; the mean of the k-th variable in X is represented by xk  and its deviation 
represented by sk, the sample standard deviation.  !xik and x 'ik represent the data after different 
pretreatment steps. Modified from (van den Berg et al., 2006). 
Unsupervised analysis 
In unsupervised analyses, all variables are unlabeled and no prior information is used. The 
most common unsupervised method in metabolomics multivariate data analysis, PCA, is 
typically used first even if complex algorithms with supervised analyses are later 
implemented (van den Berg et al., 2006). PCA is a mathematical transformation that provides 
a low-dimension view of multidimensional data by transforming a large number of 
intercorrelated variables into a smaller set of uncorrelated variables called principal 
components (PCs) while maintaining the variation of the dataset. Coordinate scores represent 
the original samples in a new space in which dimensions are linear combinations of the 
original variables, called loadings (Begam & Kumar, 2014). The first PC explains the 
maximum variance, and subsequent PCs capture the remaining variance in decreasing order. 
PCA can be used to provide a quick overview of the data, possible groupings, and outliers. 
Therefore it is a first choice in a metabolomics experiment to check whether the variance in 
the data reflects true biological difference.  
 
Supervised analysis 
In supervised analyses, prior information is used to build a matrix of predictors and a matrix 
(or a vector) of responses. The aim is to test how predictor data determine the behavior of 
response variables. Regression is an example of a supervised approach. Another main 
supervised method is classification. Importantly, regression and classification are closely 
related because most regression methods can be used as classification approaches. A wide 
variety of algorithms are available, the most common being projection to latent structures and 
orthogonal projection to latent structures, which are often combined with discriminant 
analysis to establish an optimal position with which to trace a discriminant surface that best 
separates classes. Further details about these methods can be found elsewhere (Eriksson et al., 
2004; Trygg et al., 2007).  
Table 3.2 Commomn statistycal tecniques in metabolomics. Modified from (Hendriks et al., 2011). 
Technique Use 
Artificial Neural Networks  ANN 
Machine-learning technique, relating 
inputs to an output through non-linear 
functions, mimicking neural networks of 
the brain   
ANOVA-Simultaneous Component 
Analysis  ASCA 
Finding underlying structure when the 
data are collected according to an 
experimental design  
Discriminant Analysis DA 
Methods relating explanatory variables 
to a categorical response (e.g., controls 
versus diseased subjects)   
Multi-level data ML 
Data with a multi-level structure (e.g., 
time series measured for different 
subjects)  
Multi-level Partial Least Squares 
Discriminant Analysis  ML-PLS-DA Multi-level version of PLS-DA  
Multi-level SCA  MSCA SCA method for multi-level data  
Multi-way data N-way data Data that can be meaningfully arranged in a cube or higher-way array  
N-way Partial Least Squares 
Discriminant Analysis N-PLS-DA 
Generalization of PLS-DA to N-way 
data  
Orthogonal Partial Least Squares 
Discriminant Analysis OPLS-DA 
Version of PLS-DA with a simplified 
interpretation 
Parallel Factor Analysis  PARAFAC Generalization of PCA for N-way data  
Parallel Factor Analysis ANOVA- 
Simultaneous Component Analysis PARAFASCA 
Combination of PARAFAC and ASCA 
for N-way data with an underlying 
experimental design  
 Principal Component Analysis  PCA 
Exploratory analysis method reducing 
multivariate data to a few underlying 
(principal) components  
Partial Least Squares  PLS Regression method suitable for high-dimensional collinear data  
Partial Least Squares Discriminant 
Analysis PLS-DA 
Discriminant analysis method based on 
PLS  
Principal Component Discriminant 
Analysis  PCDA 
Discriminant analysis method based on 
PCA  
Regression  Methods relating explanatory variables to continuous responses  
Random Forests  RF 
Method relating explanatory variables 
to categorical or continuous responses 
using averaging over an ensemble of 
simple models  
Simultaneous Component Analysis  SCA Generalization of PCA for simultaneous analysis of several data sets  
Support Vector Machines SVM Discriminant analysis method based on hyperplanes separating groups  
 
Analytical platforms 
Liquid chromatography coupled to mass spectrometry (LC/MS) and Surface-enhanced Raman 
spectroscopy (SERS) are the two analytical platform employed in this thesis for metabolite 
identification and metabolic fingerprinting. 
 
LC/MS 
In LC/MS, a prior chromatographic separation of a complex mixture sample is followed by 
analyte identification with MS. Currently, HPLC and ultra-performance liquid 
chromatography (UPLC) are used more frequently than any other separation technique for 
metabolic studies. Nano HPLC/UPLC is a relatively new development in chromatography 
driven by recent advances in proteomics that require decreasing inner diameters of liquid 
chromatography columns to accommodate smaller sample amounts and increased sensitivity 
(Murad et al., 2011; Petriz et al., 2015; Weinhold et al., 2015). Nano HPLC/UPLC provides 
minimal sample loss, higher sensitivity, higher peak capacity, superior separation efficiency, 
and superior coupling to MS (Sangaraju et al., 2012). The flow rate ranges from nanoliters to 
microliters per minute, and capillary columns are used instead of normal HPLC columns. 
Coupled with MS, HPLC and UPLC are powerful tools for separating and characterizing the 
majority of metabolites and yielding accurate quantitative data.  
Figure 3.3 A Nano HPLC (Dionex)- Orbitrap FTMS (Thermoscientific); B UPLC-MS/MS Xevo (Waters). 
Coupled with MS, they become powerful tools that allow the separation and characterization 
of the majority of metabolites, yielding accurate quantitative data.  
 
SERS 
 
SERS is a nondestructive analytical technique based on the inelastic scattering of a 
monochromatic light (usually provided by a laser source) by vibrating molecules. The 
applicability of Raman spectroscopy to metabolomics is limited due to the low efficiency of 
the Raman scattering process, but Raman intensity can be increased by amplifying the 
electromagnetic fields generated by the excitation of localized surface plasmons (see Figure 
3.5) if an analyte is adsorbed onto a specific metal surface or in very close proximity to it 
(typically 10 nm maximum) (Aroca, 2006; Lis & Cecchet, 2014).  
SERS exploits this arrangement and provides structure-specific vibrational spectra of 
adsorbates with extremely high sensitivity. The technique also ensures high selectivity 
because only adsorbed species can be detected. The technique facilitates investigations of 
small populations of molecules down to the single-molecule level (Bonifacio et al., 2014). 
These advantageous characteristics have made SERS a valuable tool for the nondestructive 
investigation of small-molecule populations that meets the requirements for micro and trace 
analytics, metabolomics, and biomedical and pharmaceutical studies (Vicario et al., 2015). 
From a metabolomics perspective, one of the more recent and exciting applications of SERS 
is the molecular imaging of living cells, in which silver or gold nanoparticles in suspension 
provide the necessary SERS enhancements to enable mapping molecular distributions in 
living cells and visualization of specific cellular pathways. (Palonpon et al., 2013).  
Figure 3.4 InVia Raman system (Renishaw) 
 Figure 3.5 Schematic image of plasmon oscillation for a metal nanoparticle. Metals can be considered a 
plasma composed of polarizable free electron, and positive ion core. The laser light excites the collective 
oscillations of the surface conduction electrons in a metal (surface plasmons) and the free electron coherently 
oscillate at the plasmon frequencies (ωp). This excitation results in the enhancement of the local electromagnetic 
field intensity experienced by a molecule adsorbed or in close proximity to the metal surface. The field induced at 
the surface of the nanoparticles is given by: 
   
where ε1(ω) is the complex dielectric function of the metal structure and ε2 is the relative permittivity of the 
surrounding medium. As a consequence of the presence of this secondary electromagnetic field, the intensity of the 
Raman scattered light is enhanced. The increased electromagnetic field results in enhanced Raman scattered light 
(ER) is given by  where αR is the fraction of the photons undergoing inelastic scattering under normal 
conditions and g is the average field enhancement over the particle surface (Ko et al., 2008). 
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Chapter Overview 
Chapter 4 presents the relationship between plasma C3G values and C3G amounts in the rat 
brain in the very early phase (i.e. 0-20 min) after C3G administration. We also studied fast-
forming derivatives of C3G to better describe the short-term changes. From the kinetic 
perspective, we showed that C3G is rapidly distributed into the brain. Since both metabolism 
and excretion of C3G and its derivatives affect the brain pharmacokinetics, the liver and 
kidney extracts were analyzed in a similar manner. The study design enabled us to calculate a 
set of Mean Time (MT) parameters that are useful indicators of the retention properties of 
C3G in peripheral tissues.  
Experimental section 
 
Materials 
All the chromatographic solvents were HPLC grade or LC-MS grade for the MS experiments. 
Acetonitrile, acetone, methanol p-cumaric acid and formic acid were purchased from Sigma 
Aldrich (Milan, Italy). Isotopically labelled compounds, rosmarinic acid-d7 and cinnamic 
acid-d5, were purchased from C/D/N Isotopes Inc. (Quebec, Canada). Pure anthocyanins were 
obtained from Polyphenol Laboratories AS (Sandnes, Norway) and Heparin from Schwarz 
Pharma (Milan, Italy). All chemicals were used without further purification. Ultra pure Milli-
Q water (Merck Millipore, Billerica, MA, USA) was used for the preparation of all solutions. 
Phosphate buffered saline (PBS) was prepared as following: 6.03 mM Na2HPO4, 3.91 mM 
NaH2PO4 and 139 mM NaCl (Carlo Erba, Milan, Italy) were dissolved in MilliQ water 
(Millipore) and pH was adjusted to 7.4 with HCl. 
 
Study design and protocol 
 
Figure 4.1 Experimental design and targeted analytical workflow. 
The experiment was designed as a one-component pharmacokinetic study with quantitative 
analysis of the target metabolites in selected organs (liver, kidney and brain) and biofluids 
(plasma and urine), (see Figure 4.1). The principal aim of this study was to characterize the 
presence of C3G in the anaesthetized rat brain. The three main questions posed were: i) is 
there any relationship between [C3G] in the blood and in the brain?; ii) what is the time 
needed for C3G to distribute in the brain?; iii) for how long is biologically meaningful C3G 
concentration maintained in the brain? To address these questions, C3G was administered 
intravenously, so as to prevent inter-individual variability in gastrointestinal absorption.  
Twenty-two male Wistar rats (Rattus Norvegicus, Harlan Italy S.r.l.), of same age (15 weeks), 
293-390 g of body weight, were used. The rats were randomly divided into 5 groups, 
according to the time that elapsed after intravenous administration of the test compound, and 
one control group. Each time point was represented by four biological replicates. All animals 
were allowed to acclimate to the animal facility of the University of Trieste for at least 2 week 
before studies were initiated. The experimental design was vetted and approved by the 
bioethical committee of the University of Trieste (internal code 140PAS14), according to the 
provisions of the European Community Council Directive (Directive 2010/63/EU of the 
European Parliament and of the Council of 22 September 2010 on the protection of animals 
used for scientific purposes, 2010). The animals (n=22) were maintained in cages in a room at 
23 ± 2°C, 50-60% humidity with a 12-hour light-dark cycle. The night before the experiment, 
food was withdrawn from the cages but water was given ad libitum. On the day of the 
experiment, the rats were anesthetized with intra-peritoneal administration of 
tiletamine/zolazepam (1:1, 25 mg/kg body weight) and xylazine (10 mg/kg body weight). 
During anesthesia (10 min in all cases), the heart and ventilation rate were monitored. The 
rats were placed on their backs, with the ventral side up and with the legs spread separately on 
a thermo-isolated support. The penis was extruded by sliding the prepuce downwards. The 
dorsal penis vein was then seen along both sides of the penis and exactly 10 min after 
anesthesia 0.2 mL PBS without (control group) or with (treated group) 668 nmol cyanidin 3-
glucoside (C3G) in PBS was injected using a 24-G hypodermic needle. Then the injection site 
was pressed with a swab for a few seconds, and the glans was encouraged to retract to prevent 
further bleeding (Waynforth & Flecknell, 1992). One min before sacrificing the rats, sodium 
heparin (0.1 ml, 500 IU) was injected again into the dorsal penis vein, exposed in the same 
way. Exactly 10 min after anesthesia and the corresponding time point after I.V. 
administration (0.25, 5, 10, 15, 20 min), the rats were sacrificed by decapitation. Blood 
draining and excision of the organs were carried out according to the literature (Andreja 
Vanzo et al., 2011). Urine was collected through the urinary bladder with a syringe. Kidneys, 
liver and brain were washed with mQ water, immediately frozen in liquid nitrogen and stored 
at -80 °C. 
 
Organ collection and extract preparation 
Immediately after sampling, 5 mL of blood were transferred into ice-cold (-20 °C), 
deoxygenated aqueous 95 % methanol in a ratio 1:9 (v/v). The urine was weighted and 
transferred into ice-cold, deoxygenated aqueous 95 % methanol at a ratio of 1:9 (w/v). Frozen 
kidneys, liver and brain were grounded under cryogenic conditions (-196° C) to 5 µm 
particles in a CryoMill (Retsch, Germany), using a single 25 mm i. d. steel ball (30 seconds, 
25/sec frequency). The pulverized tissue was rapidly transferred (without thawing) into ice-
cold, deoxygenated aqueous 95 % methanol at a ratio of 1:9 (w/v). Cinnamic acid-d5, as 
internal standard, was dissolved in the aqueous methanol at concentration of 0.1 mg/L for the 
monitoring of the extraction protocol in biofluids and tissues.  
All samples were extracted with an orbital shaker for 10 min at room temperature. The 
methanol extracts were then centrifuged for 5 min at 3600 rpm at 4 °C, decanted under a 
stream of nitrogen in 50 mL dark glass vessels and stored at -80 °C. 
Clean-up of extracted samples in methanol was performed by solid phase extraction (SPE), as 
previously described (Passamonti et al., 2003). Briefly, 5 mL of extracted samples were 
evaporated on a rotary evaporator and reconstituted in 10 mL of acidified water. 
Anthocyanins were extracted by solid-phase adsorption onto a hydrophobic matrix (Sep-Pak 
C18, 0.35 g, Waters, Milford, MA). Anthocyanins were eluted with methanol, evaporated to 
dryness and immediately dissolved with 500 µL of methanol:water (50:50). Rosmarinic acid, 
as internal standard at 1 mg/L, was added in the aqueous methanol for allowing the 
adjustment of quantitative recovery after sample reconstitution. Samples were filtered through 
a 0.22 µm PVDF filter (Millipore, Bedford, MA) into HPLC vials for the subsequent 
quantitative analysis. 
 
Quantitative analysis 
C3G and its derivatives were quantitatively analyzed by an ultra performance LC (UPLC) 
system coupled to a triple quadrupole (TQ) mass spectrometer.  
The UPLC-MS/MS method was chosen to take advantage of the selectivity and sensitivity 
combined to wide dynamic range of MRM detection in tandem spectrometry, thus allowing 
the simultaneous quantitation of the main expected metabolites throughout the experiment. A 
Waters Acquity UPLC (Waters, Manchester, UK) controlled by MassLynx 4.1 was used. 
Separation of the target metabolites and 2 deuterated internal standards was performed on a 
reversed phase (RP) ACQUITY UPLC 1.8 µm 2.1 x 100 mm HSS T3 column (Waters) 
protected with an Acquity UPLC BEH HSS T3 1.8 µm, 2.1 x 5 mm precolumn (Waters), at 
40° C and under a mobile phase flow rate of 0.28 mL/min. Mobile phases of 0.1% formic acid 
in Milli-Q water (A) and 0.1% formic acid in acetonitrile (B) were used. Chromatographic 
separation was performed using a multistep linear gradient as follows: 0 min, 5% B; 0-3 min, 
5%-20% B; 3-4.30 min; 20% B; 4.30-9 min, 20%-45% B, 9-11 min, 45%-100% B, 11-14 
min, 100%; and 14.01-17 min, 5% as equilibration time. Injection volume was 10 µL, and the 
samples were kept at 4 1/4C throughout the analysis.  
The TQ mass spectrometer used was a Waters Xevo TQ (Milford, Massachusetts, USA) 
coupled with an electrospray interface. Quantification and confirmation of the anthocyanins 
were performed using two MRM (multiple reaction monitoring) transition for each 
compound, using the conditions previously reported (Andreja Vanzo et al., 2011). The first 
transition, corresponding to the most abundant fragment, was used as quantifier ion, and the 
second as qualifier ion. For calibration, standard anthocyanins were serially diluted in 
aqueous methanol (50:50), in a concentration range 0.01 µg/L - 100 mg/L. The range of 
calibration curves was obtained on the basis of the linearity of the responses. Acceptable 
linearity was achieved when the coefficient of calibration curves (R2) was at least 0.99. 
Quantitative data were processed with Targetlynx software (Masslynx, Waters). C3G and its 
derivatives were quantified with the appropriated standard reference with the exception of 
isoPN3G, expressed as equivalent of PN3G.  
 
Recovery and residual blood correction 
According to the published method (Andreja Vanzo et al., 2011), the amounts in each matrix 
were calculated by taking into consideration the appropriate recovery, and by assuming that 
rat plasma volume is 3.375 µL/g of rat weight (International Life Sciences Institute, 1994). 
The correction for the residual blood in the brain was performed as proposed in (Fridén et al., 
2010), by subtracting the estimated amount of C3G, PNG and PT3G in the effective plasma 
space. 
 
Pharmacokinetics analysis 
Pharmacokinetic parameters of I.V. administration of C3G in rats were determined from the 
mean (n=4) plasma concentration–time data by both non-compartmental and compartmental 
analysis as implemented in PK-Solver (version 2.0) (Zhang et al., 2010). The statistical and 
graphical analyses were accomplished using the software package Prism version 6.0 
(GraphPad Software Inc., San Diego, Calif., USA) and Origin 2015 (OriginLab). 
 
Non-compartmental analysis (NCA) 
Non-compartmental analysis (NCA) is a standard technique of PK analysis. NCA is easier to 
apply and relies on fewer assumptions than compartmental modeling. Standard NCA assumes 
linear PK, i.e. all transport processes are assumed to follow first-order kinetics (P Veng-
Pedersen, 2001), and does not provide a mechanistic description. 
For NCA, the area under the concentration-time (AUC) curve was calculated using log/linear 
trapezoidal method from time 0 to the last sampling point 20 min after administration. This 
means that linear interpolation is used for ascending parts of the curve and logarithmic 
interpolation is used for descending parts of the curve. Plasma concentrations are assumed to 
decline mono-exponentially between two measured concentrations for the descending part of 
the curve. The PK parameters determined were the concentration at time 0 (C0), the terminal 
elimination rate constant (λz), the terminal elimination half-life (t1/2), the apparent volume of 
distribution at terminal phase (Vz), the relative volume of distribution at steady state (Vss), and 
the total body clearance (CL).  
The mean time (MT) parameters dealing with the tissue distribution of C3G were calculated 
from the moments of the concentration-time curve in plasma and specific target tissues, as 
described (McNamara et al., 1987; P. Veng-Pedersen, 1989). Briefly, Mean residence time 
(MRT) is the time that a molecule stays in the body, excluding the gastrointestinal tract. MRT 
was calculated as the ratio of the area under the first moment concentration time curve 
(AUMC) divided by the area under the zero moment curve (AUC). The terminal elimination 
half-life (t1/2) and AUC respective to C3G derivatives were also calculated to determine 
exposure to any derivatives compared with the parent compound. Maximum plasma 
concentrations (CMAX), and their times of maximal occurrence (TMAX) were taken directly 
from the observed data. 
 
Two-Compartment Model Analysis (TCMA) 
Mean concentrations of C3G in plasma versus time were further analyzed by a two-
compartment, mammillary open, IV bolus model, with first order elimination (Figure 2).  
 
Here, the two-compartment model is envisioned with a central compartment, which includes 
the plasma vascular space (circulation), and a peripheral compartment, which corresponds to 
some extravascular "tissue" space. Total body clearance (CL) accounts for irreversible 
removal of drug from the plasma or central compartment (volume V1), while distribution 
clearance (CLD) effects C3G uptake and removal from the peripheral compartment (V2) by 
flow/permeability mechanisms. Under these conditions, the representative equations for the 
Figure 4.2 Hybrid 2 compartment model. The information contained in the plasma concentration versus time profile 
can be used to describe the disposition of the drug in the body, in terms of mean times spent in the different 
compartments (MRTcentral and MRTperipheral), number of visits (Ic) in these compartments and mean duration of 
one visit (MTT). 
drug concentrations in blood or plasma (Cp) and in peripheral space (Ct) after an IV bolus 
dose into the central compartment are:  
Cp(t ) = Ae−αt + Be−βt  
and 
Ct(t ) = C(e−αt − e−βt )  
where Cp(t) and Ct(t) are the concentrations of C3G in the two compartments at time t; α and β 
are the Eigen values, macro-constants characterized by the first-order rate constants for C3G 
transfer out of and into the central compartment, k12 and k21, respectively, and the first-order 
rate constant for drug elimination from the central compartment, k10. 
 
α =
(k10 + k12 + k21)+ (k10 + k12 + k21)2 − 4k10 i k21{ }
1
2
2  
 
β =
(k10 + k12 + k21)− (k10 + k12 + k21)2 − 4k10 i k21{ }
1
2
2  
and A, B and C are pre-exponential factors defined in terms of the dose (D), V1, and k21, 
 
A = DV1
i
(k21 −α )
(β −α )  
 
B = DV1
i
(k21 − β )
(α − β )  
 
C = DV1
i
k21
(α − β )  
Since plasma concentrations often span a wide range, it is useful to employ a weighting 
procedure for the raw data that allows to fit low concentrations and high concentrations 
simultaneously. Data for model fitting were iteratively reweighted by modulating the 
reciprocal of the squared predicted concentrations (1/C2pre). The goodness-of-fit was assessed 
by visual inspection of the residual plots, parameter estimation precision, correlation (R2) 
between the observed and predicted concentration values, weighted sum of squared residuals 
(WSS), Akaike's information criterion (AIC), and Schwarz criteria (SC). The lower the WSS, 
AIC, and SC, the more appropriate is the selected model (Figure 3). 
 In addition, the information contained in the plasma concentration versus time profile were 
used to describe the disposition of the drug in the body, in terms of mean times spent in the 
different compartments (MRTcentral and MRTperipheral), number of visits (Ic) in these 
compartments and mean duration of one visit (MTTC), according to the methods proposed by 
Kong and Jusko (Kong & Jusko, 1988). 
Figure 4.3 Comparison between different weightings schemes. 
Results and discussion 
Table 1 reports the concentrations of C3G and other anthocyanins measured in plasma of 
anaesthetized rats over a period of 0-20 min after I.V. administration of 668 nmol C3G. In 
accordance with previous PK studies, the elimination of C3G from plasma appeared to follow 
a first-order kinetics. The disappearance of C3G was very fast, its biotransformation was 
rapid and substantial, allowing for the quick appearance of some derivatives in the circulation. 
D3G appeared transiently in plasma only at 2 min. PT3G was detected in plasma only in trace 
amounts within the first 5 min. No aglycones or conjugated derivatives were detected. 
Table 2 reports the concentrations of C3G and other anthocyanins measured in the brain, the 
liver and the kidneys. C3G distribution and methylation to PN3G were very rapid in these 
tissues, where PT3G was also found. The amounts recovered in the urine are reported in 
Table 3. Rat urine showed relatively high amounts of C3G and major metabolites. As much as 
15% of the injected dose was recovered 5 min after the injection. 
A noteworthy feature is the high rate of C3G disappearance following I.V. administration, 
thereby making it an analytical challenge to detect plasma C3G at sufficient amounts for its 
PK parameters to be determined.  
 
Table 4.1 Mean plasma concentrations (nM) of C3G and its derivatives in Wistar rats following intravenous 
administration of 668 nmol of C3G. Results are expressed as mean ± SEM (n=4). 
Time 
(min) C3G PN3G PT3G D3G M3G PG3G TOT 
0.25 354.84 ± 54.19 33.68 ± 5.51 2.20 ± 1.05 nd 9.13 ± 3.46 4.50 ± 0.62 404.34 ± 64.83 
2 93.80 ± 9.01 13.05 ± 2.35 4.95 ± 3.16 12.81 ± 10.46 95.83 ± 61.71 1.89 ± 0.17 222.33 ± 86.86 
5 72.19 ± 5.47 12.31 ± 1.37 1.71 ± 1.39 nd 16.45 ± 13.08 2.01 ± 0.28 104.67 ± 21.58 
15 17.50 ± 2.04 3.73 ± 0.94 nd nd 3.67 ± 0.14 1.90 ± 0.19 26.80 ± 3.31 
20 18.78 ± 4.06 3.40 ±  0.22 nd nd 8.60 ± 3.88 1.55 ± 0.13 32.33 ± 8.29 
        
AUC0-20  
(nM min) 1165.23 174.77 nsd nsd 343.45 40.41 1825.57 
Half life  
(min) 6.90 8.16 nsd nsd 5.29 44.67 5.36 
 
nd Not detected; nsd data not sufficient to estimate the terminal slope; AUC0-20, Area Under the Curve from 0 to 20 
min; t1/2, Half-life; C3G, cyanidin-3-O-glucoside; D3G, delphinidin-3-O-glucoside; PN3G, peonidin-3-O-
glucoside; PT3G, Petunidin-3-O-glucoside; M3G, malvidin-3-O-glucoside; PG3G, Pelargonidin-3-O-glucoside. 
 
Table 4.2. Mean concentrations of C3G and its derivatives in liver, kidneys and brain of Wistar rats following 
intravenous administration of 668 nmol of C3G. Concentrations are expressed as mean ± SEM (n=4).  
 
* pmol min g-1 L-1; N/A Not applicable; nd, not detected; nsd data not sufficient to estimate the terminal slope; 
AUC0-inf, Area under curve; MTTB, Mean Transit Time in the brain; MTTK, Mean Transit time in kidneys; 
MTTL, Mean Transit Time in the liver. 
Liver 
Time 
(min) 
C3G 
(pmol/g) 
PN3G 
(pmol/g) 
PT3G 
(pmol/g) 
isoPN3G 
(pmol/g) 
0.25 56.61 ± 11.79 539.38 ± 71.33 1.23 ± 0.59 13.86 ± 4.32 
2 19.22 ± 1.99 317.61 ± 35.86 2.42 ± 0.08 6.19 ± 2.09 
5 20.91 ± 2.61 364.74 ± 44.85 1.09 ±0.52 15.85 ± 1.82 
15 11.02 ± 2.24 216.10 ± 36.06 1.60 ± 0.44 1.39 ± 1.14 
20 5.54 ± 0.33 100.84 ± 6.33 3.06 ±0.19 0.64 ± 0.25 
     
AUC0-t (pmol/g min) 345.29 5610.12 33.85 145.57 
Half-life (min) 8.15 9.99 nsd 3.18 
MTTL (min) 1.43 3.93 nsd N/A 
     
Kidney 
Time 
(min) 
C3G 
(nmol(g) 
PN3G 
(nmol/g) 
PT3G 
(pmol/g) 
 
0.25 1.69 ± 0.47 1.99 ± 0.55 2.04 ± 0.59  
2 1.40 ± 0.16 1.56 ± 0.18 2.82 ± 0.28  
5 0.58 ± 0.08 0.85 ± 0.08 2.40 ± 0.13  
15 0.57 ± 0.17 0.89 ± 0.22 2.29 ± 0.07  
20 0.44 ± 0.04 0.90 ±0.14 2.53 ± 0.26  
AUC0-t (nmol/g min) 14.32 20.36 48.13* 
 
Half-life (min) 11.66 20.80 135.08 
 
MTTK (min) 8.54 23.11 187.44 
 
     
Brain 
Time 
(min) 
C3G 
(pmol/g) 
PN3G 
(pmol/g) 
PT3G 
(pmol/g) 
 
0.25 40.46 ± 9.67 nd nd  
2 7.48 ± 0.79 2.07 ± 1.18 1.15 ± 0.62  
5 7.05 ± 0.55 0.70 ± 0.30 1.01 ± 0.46  
15 2.18 ± 0.58 0.40 ± 0.38 2.45 ± 0.22  
20 2.21 ± 0.44 0.37 ± 0.13 1.90 ± 0.60  
AUC0-t (pmol/g min) 119.89 17.10 32.42  
Half-life (min) 8.80 15.57 nsd  
MTTB (min) 0.43 8.61 nsd  
     
Plasma Pharmacokinetics of C3G 
The plasma PK parameters, calculated by both non-compartmental and two compartment 
model analysis, are reported in Table 4. Notably, half-life (t1/2), volume of distribution at 
steady state (Vss) and total body clearance (CL) were similar if calculated by either method. 
The plasma concentrations of C3G at time zero (C0) were 550 or 429 nM, if calculated by 
either compartmental or non-compartmental analysis, respectively. The results allow several 
novel insights into C3G distribution and metabolism, and they also corroborate findings 
previously made in the same (Andreja Vanzo et al., 2011) or in other rodent species 
(Marczylo et al., 2009). 
The mean half-life of C3G was less than 8 min, meaning that ca. 10% of the residual amount 
of C3G was eliminated per min. Accordingly, we can estimate that the time window needed 
to accurately describe complete elimination is no more than 1 hour (considering the general 
rule of a thumb for a complete elimination in 5-6 half-lives, which is in our case 40-50 min). 
At the steady state, the volume of distribution of C3G was 4.58 L, which is much greater than 
total body water (Brown et al., 1997), suggesting that C3G is extensively distributed in tissues. 
As a consequence, the plasma concentration cannot be used as a proxy for predicting the 
concentration in tissues, with the possible exception of brain, as discussed below.  
It is noteworthy that the total body clearance of C3G was 0.49 L/min, a figure that is 
significantly higher than the cardiac output (0.10 L/min). Therefore, blood-flow independent 
elimination can be assumed, e.g. by rapid degradation to undetectable products or by direct 
metabolism occurring in the blood (plasma, red blood cells, and/or endothelial surface). 
Indeed, anthocyanins can undergo both spontaneous and enzyme-catalyzed decomposition to 
a phenolic acid and the unstable phloroglucinol aldehyde (2,4,6-trihydroxybenzaldehyde), 
(Fleschhut et al., 2006).  
 
Non-Compartmental Analysis 
According to NCA, the calculated maximum plasma concentration of C3G (C0) was 429 nM 
at time 0, the terminal elimination rate constant λz was 0.1 min-1 and the terminal elimination 
half-life (t1/2) was 6.9 min. The mean residence time (MRT) was 8.72 min, the apparent 
volume of distribution at terminal phase (Vz) was 4.92 L, the relative volume of distribution 
at steady state (Vss) was 4.31 L, and the total body clearance (CL) was 0.49 L/min.  
 
Two-compartment model analysis 
The disappearance of C3G from plasma could be also fitted to a two-compartment, 
mammillary open model, with first order elimination (R2 = 0.9992; WSS = 0.14; AIC = -1.93; 
SC = -3.49), as shown in Figure 4: a very rapid decline in the first 2 min (distribution phase) 
that was followed by a slower declining phase (elimination phase).  
The physiological parameters resulting from this model were: i) the volume in the central 
compartment (V1, 1.21 L) ii) the volume in the peripheral compartment (V2, 3.36 L, 
suggesting that the major fraction resided in the peripheral compartment), iii) the distribution 
half-life (t1/2d, 0.30 min, suggesting that after 18 s, half of the compound had been already 
cleared from the plasma. In other words, it takes ca. 8 seconds for distribution to go to 50% 
completion and between 25 to 42 seconds for distribution to go to completion), iii) the 
elimination half-life (t1/2e, 7.41 min, so that during yhe terminal phase of elimination ca. 10% 
of the residual amount of C3G is eliminated per min), iv) the total body clearance (CL, 0.49 
L/min), v) the distribution clearance (CLd, 1.76 L/min) and vi) the volume of distribution at 
steady state (Vss , 4.58 L).  
Figure 4.4 Two-compartment model fitting to the C3G plasma concentration-
time profile in Wistar rats following intravenous administration of 668 nmol of 
C3G (R2 = 0.9992; WSS = 0.14; AIC = -1.93; SC = -3.49). Concentrations are 
expressed as mean ± SEM (n=4). 
When distribution equilibrium is achieved, 0.24% of C3G is present in plasma and 99.76% is 
distributed outside plasma. A diagram of this model is shown in Figure 5. 
Table 4.3. Pharmacokinetic parameters of intravenous administration of 668 nmol of C3G in Wistar rats. 
Non-compartmental  
analysis Two-compartment model analysis 
Parameter Value Parameter Value Parameter Value 
λz (min-1) 0.10 a (nM) 442.79 b (nM) 107.68 
Tmax (min) 0.25 α (min-1) 2.29 β (min-1) 0.09 
Cmax (nM) 354.84     
C0 (nM) 429.12 k10 (min-1) 0.41 Cld (L/min) 1.76 
AUC0-inf (nM*min) 1352.14 k12 (min-1) 1.45 Cld (L/min kg) 5.18 
AUMC (nM*min2)  11789.96 k21 (min-1) 0.52 CL (L/min) 0.49 
MRT (min) 8.72 t1/2d (min) 0.30 CL (L/min/kg) 1.46 
Vz (L) 4.92 t1/2e (min) 7.41 AUC0-inf (nM*min) 1334.49 
CL (L/min) 0.49 C0 (nM) 550.47 AUMC (nM*min2) 12394.67 
t1/2 (min) 6.90 V1 (L) 1.21 MRT (min) 9.22 
Vss (L) 4.31 V2 (L) 3.36 MRTC (min) 2.44 
  V1 (L/kg) 3.57 MRTP (min) 6.78 
  V2 (L/kg) 9.90 MTT (min) 0.54 
  V2/V1 2.77 MTTp (min) 1.91 
  Vss (L) 4.58 IC 3.55 
  Vss (L/kg) 12.62 Kp 2.77 
 
a, T0 intercept of distribution kinetics; α, Exponent of the polyexponential equation (slope factor); AUC0-inf, Area 
under curve out to infinity; AUMC, Area Under the first Moment Curve from time 0 to infinity; β, Exponent of 
the polyexponential equation (slope factor); b, T0 intercept of elimination phase; C0, back-extrapolated drug 
concentration following rapid bolus iv administration; CLd, Distribution clearance; CL, Total body clearance; 
Cmax, Maximum observed concentration; IC, number of circulations; k10, rate constant for elimination of drug 
from central compartment to outside body; k12, rate constant for distribution of drug from central compartment to 
peripheral compartment; k21, rate constant for redistribution of drug from peripheral to central compartment; 
MRT, Mean residence time; MRTC, Mean residence time in the central compartment; MRTP, Mean residence 
time in the peripheral space; MTT, Mean transit time; MTTp, Mean Transit Time in the peripheral space; tmax, 
Time of occurrence of Cmax; t1/2, Terminal elimination half-life; t1/2d, Distribution half-life; t1/2e, Elimination 
half-life; V1,Volume of central compartment; V2, Volume of peripheral compartment; Kp, partition coefficient 
over the two compartments; Vss, Volume of distribution at steady state; λz, First order terminal elimination rate 
constant. 
 
Peripheral Bioavailability 
The so-called "peripheral bioavailability" of C3G may be evaluated by examining the various 
mean time (MT) parameters in terms of the tendency of the C3G molecules to distribute into 
and remain in the peripheral space. 
The MT parameters indicate that C3G molecules tend to spend a longer time (73.51 % of its 
MRT) in the peripheral space than in the central compartment. This speaks in favor of an 
accumulation pattern for C3G molecules. The mean residence time of C3G in the body (MRT, 
9.21 min) is the sum of the mean residence time in the peripheral space (MRTP, 6,77 min) and 
the mean residence time in the central compartment or circulation (MRTC, 2.44 min); the 
partition coefficient between the peripheral and central spaces (Kp, calculated as 
MRTP/MRTC) was 2.77; iii) the mean transient time of C3G molecules in the peripheral space 
(MTTP 0.14 min), which is defined as the mean time needed for C3G molecules to return to 
the general systemic circulation (central compartment) subsequent to entering the peripheral 
space; and iv) the number of circulations made by a molecule on average before being 
eliminated (IC, calculated as MRTP/ MTTP) was 3.56. In other words, while seven molecules 
are being distributed from the central to peripheral space, two molecules are being eliminated.  
Figure 4.5 Hybrid 2 compartment model. 
Tissue pharmacokinetics of C3G and its metabolites 
The concentrations-time courses of C3G in selected tissues are shown in Figure 6. C3G, 
PN3G and PT3G could be detected in liver, kidneys and brain (Figure 6 and Table 2).  
The amounts of C3G found in tissues were in descending order of kidney (0.44 – 1.69 
nmol/g), liver (5.64 – 58.61 pmol/g) and brain (2.41 – 44.11 pmol/g). The AUC values of 
C3G in the brain and in the liver were similar (345.3 and 119.9 pmol/g min, respectively) and 
both figures were different from the value of the kidneys (14.3 nmol/g min), as reported in 
Table 2.  
Since this experiment was focused on the distributive phase of the concentration-time profile 
in both the sampled tissues and plasma, the data enabled us to estimate the Mean Transit Time 
in each specific tissue (MTTi). Under these experimental conditions, this value is a good 
descriptor of tissue distribution differences (McNamara et al., 1987). Distribution of C3G 
Figure 4.6 Concentrations-time courses of C3G in selected tissues. 
occurred most quickly in the brain (MTTb, 0.43 min), followed by the liver (MTTl, 1.43 min) 
and then the kidney (MTTk, 8.54 min).  
The amounts of PN3G recovered in tissues were in descending order of kidney (0.90 – 1.99 
nmol/g), liver (100.84 – 539.38 pmol/g) and brain (0.37 – 2.07 pmol/g). The 4' positional 
isomer isoPN3G was detected here as an expected metabolite, based on a critical re-
assessment (Pojer et al., 2013) of previous data obtained by our group. It was here confirmed 
to be a minor peak, around 2.59% of PN3G, only in the liver. The AUC of PN3G in the 
kidneys and in the liver was 116.5 times and 32.10 times higher than in plasma, respectively, 
indicating strong metabolic capacity. For comparison, the AUC in the brain was only 9.78% 
of that in plasma.  
The presence of PN3G in the sampled tissues (MTTl, 3.93 min; MTTk, 23.11 min; MTTb, 
8.61 min) was significantly longer than C3G. 
 
Significance of C3G in the brain 
At 15 sec after the intravenous administration, C3G concentration in plasma was in the same 
physiological range, as observed in the post-absorption phase (Tsuda et al., 1999). Under 
these conditions, the C3G levels reached in the brain were approximately 50 nM (The 
amounts found in the brain were 2.41 – 44.11 pmol/g.), i.e. a value at which it could interact 
with biological targets eliciting biological responses. 
Shortly after, plasma C3G levels rapidly declined, probably due to the rapid disposition of the 
injected bolus. However, under conditions that simulate the normal peroral consumption, 
absorption from the gastro-intestinal compartment lasts longer, so it can be speculated that 
plasma C3G concentration remains elevated for a longer time, as previously shown 
(Passamonti et al., 2003; A. Vanzo et al., 2008).  
Importantly, the parallel decline of C3G concentrations in the brain and those measured in 
plasma, as well as the MTTB (0.43 min), also suggests no excessive retention of the 
compound in the brain tissue. Such an extensive distribution of C3G, also in the brain, despite 
the unfavorable chemical properties of the molecule (hydrophilic molecule) in terms of cell 
membrane passage, is probably a result of the action of a specific transport mechanism (Kell, 
2013). Indeed, C3G has been shown to pass the endothelial cell membrane in a short time 
frame (<1 min) (Ziberna et al., 2012). 
 As a result, the levels of C3G in the brain linearly correlated with the plasma values, thus 
providing a measure of the capacity to maintain brain C3G in equilibrium with C3G in the 
circulation. Furthermore, our data suggest a relatively low inter-individual variability of the 
blood-brain barrier permeability with respect to C3G under the chosen experimental 
conditions. Therefore, it can be suggested that the plasma C3G concentrations are a good 
indicator of the C3G levels in the brain. This implies that further pharmacokinetic studies 
might be designed accordingly, e.g. by increasing the number of blood samples taken from a 
single animal, following C3G administration. In the case of oral administration, notably 
entailing large inter-individual variability of C3G levels in the circulation, any inter-
individual variability in plasma levels of C3G should be accompanied by a corresponding 
variability in C3G brain levels.  
To demonstrate the intactness of the blood-brain barrier under the chosen experimental 
conditions, we showed that the anthocyanin’s profile in the brain (with AUC C3G 
>PT3G>PN3G, Table 2) was clearly different from that observed in plasma (with AUC 
Figure 4.7 The ratio between the total anthocyanins concentration in the studied tissues and the total 
anthocyanin concentration in plasma, at each time point. 
C3G>M3G>PN3G>PG3G, Table 1).  
C3G uptake from plasma into the studied organs was also estimated as the sum of 
anthocyanins detected in tissues versus plasma. We found that this ratio increased over time 
in all tissues, except in the brain (Figure 7). Indeed, the brain was the only organ in which no 
substantial metabolism was detected, and a linear correlation between plasma and brain C3G 
levels was observed (Figure 8) over a physiologically relevant range of C3G plasma 
concentration (18.78 – 354.84 nM). No correlation could be observed with the other 
metabolites, once more suggesting the selectivity of the blood-brain barrier. 
 
Urinary excretion 
Urine concentrations of C3G and methylated derivatives in Wistar rats following intravenous 
administration of C3G were determined over a period of 0 – 20 minutes. Urine concentration-
time data are listed in Table 5. We detected the urinary excretion after 2 min, which 
represents the time needed for C3G to undergo uptake, metabolism and excretion in the 
kidneys. Rat urine showed relatively high amounts of C3G and major metabolites. Moreover, 
15% of the injected dose was recovered in 5 min after the injection. 
 
Figure 4.8 Positive linear correlation (R2, 0.9427) between plasma and brain C3G concentrations in individual 
rats. 
Table 4.4. Urine concentrations of C3G and its derivatives in Wistar rats following intravenous administration of 668 nmol 
of C3G. 
Time 
(min) 
C3G 
(nmol/g) 
PN3G 
(nmol(g) 
PT3G 
(pmol(g) 
D3G 
(nmol/g) 
M3G 
(pmol/g) 
PG3G 
(pmol/g) 
TOT 
(nmol/g) 
0.25 0.02 ± 0.01 0.01 ± 0.00 4.58 ± 2.84 0.02 ± 0.01 28.35 ± 17.87 1.57 ± 0.40 0.09 ± 0.05 
2 2.69 ± 0.82 1.48 ± 0.41 3.30 ± 1.59 0.03 ± 0.00 9.57 ± 4.52 7.92 ± 2.59 4.23 ± 1.24 
5 20.20 ± 2.61 6.54 ± 0.33 nd 0.05 ± 0.01 5.15 ± 1.88 47.09 ± 4.16 26.84 ± 2.96 
15 11.95 ± 6.53 5.67 ± 2.24 nd 0.02 ± 0.01 3.17 ± 1.64 33.22 ± 16.09 17.68 ± 8.81 
20 5.66 ± 1.31 5.16 ± 1.11 nd 0.03 ± 0.01 0.00 ± 0.00 20.98 ± 5.61 10.87 ± 2.44 
nd, Not detected. 
 
Conclusions 
Our study provides long-needed quantitative data about C3G distribution in rat biofluids and 
organs, including the brain. Moreover, the obtained results are now available for designing 
and interpreting the intervention trials in animals and humans, which are aiming at 
establishing the link between intake of anthocyanin-rich food or supplements and the 
protection against age-related cognitive dysfunctions.  
However, our study has several important limitations. Our study was done on a small number 
of animals, and shall be repeated in a larger trial to confirm our novel findings related to the 
identification of C3G in the brain. However, these pioneering experiments (first documented 
trial of C3G in short-term pharmacokinetics, i.e. we sacrificed 3 animals at time point 15 sec) 
are in agreement with the 3R principles for animal research that warrants the reduction of 
animals for risky hypotheses-based experiments.   
Another issue is that in general the total recoveries from anthocyanin extraction procedures, 
similar to those used in the current study, are low (38.6-57.7% from plasma, and 21.4-46.4% 
from tissues in (Andreja Vanzo et al., 2011)). Hence it is possible that the apparently poor 
total recovery of the dose can be assigned to the incomplete extraction and detection. Indeed, 
the poor recovery may be hypothesized to be due to the very strong binding of anthocyanins 
with proteins in the sample (Tang et al., 2014; Wiese et al., 2009).  
Anthocyanins can also be metabolized into yet unidentified C3G derivatives, or covalently 
bound to proteins in plasma or inside cells, or to other polymers during the extraction and 
analysis methods.  
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Chapter  5. A data analysis pipeline for an 
untargeted metabolomic workflow 
 
 
 
 
 
 
Chapter Overview 
Chapter 5 presents the development of a validation framework and accuracy measures applied 
to an untargeted metabolomic workflow. The experiment deals with the analysis of hundreds 
of samples, characterized by several thousands of metabolic features, that is impossible to 
analyze manually. Thus, we discuss the key elements of the workflow, such as multivariate 
and machine learning data analysis and data visualization tools, to provide an integrated 
hypothesis building analysis pipeline for the selection of biomarker candidates.  
Experimental section 
 
Materials 
All the chromatographic solvents were HPLC grade or LC-MS grade for the MS experiments. 
Acetonitrile, acetone, methanol p-cumaric acid and formic acid were purchased from Sigma 
Aldrich (Milan, Italy). Isotopically labelled compounds, rosmarinic acid-d7 were purchased 
from C/D/N Isotopes Inc. (Quebec, Canada). Pure anthocyanins were obtained from 
Polyphenol Laboratories AS (Sandnes, Norway) and Heparin from Schwarz Pharma (Milan, 
Italy). All chemicals were used without further purification. 
Ultra pure Milli-Q water (Merck Millipore, Billerica, MA, USA) was used for the preparation 
of all solutions. Phosphate buffered saline (PBS) was prepared as following: 6.03 mM 
Na2HPO4, 3.91 mM NaH2PO4 and 139 mM NaCl (Carlo Erba, Milan, Italy) were dissolved in 
MilliQ water and pH was adjusted to 7.4 with HCl. 
 
Study design and protocol 
The experiment was designed as a one-component pharmacokinetic study with untargeted 
profiling of brain, plasma and urine (see Figure 5.1). The experimental design was vetted and 
approved by the bioethical committee of the University of Trieste (internal code 140PAS14), 
according to the provisions of the European Community Council Directive (Directive 
2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the 
protection of animals used for scientific purposes, 2010). More details about surgery 
procedures and animals handling can be found in chapter four. Briefly, Twenty-two male 
Wistar rats (Rattus Norvegicus, Harlan Italy S.r.l.), of same age (15 weeks), 293-390 g of 
body weight, were randomly divided into 5 groups, according to the time that elapsed after 
intravenous administration of the test compound, and one control group. The rats were 
anesthetized with intra-peritoneal administration of tiletamine/zolazepam (1:1, 25 mg/kg body 
weight) and xylazine (10 mg/kg body weight). They received i.v. administration of 0.2 mL 
PBS, with (test) or without (control) 668 nmol cyanidin 3-glucoside. According to a previous 
study, the same dose of cyanidin 3-glucoside made it possible to observe a peak plasma 
concentration of about 1.5 uM cyanidin 3-glucoside 1 min after i.v. administration (Vanzo et 
al. 2011). One min before sacrificing the rats, sodium heparin (0.1 mL, 500 IU) was injected. 
10 min after anesthesia and the corresponding time point after i.v. administration (0.25, 5, 10, 
15, 20 min), the rats were sacrificed by decapitation. Urine was collected through the urinary 
bladder with a syringe. The brain was washed with mQ water, immediately frozen in liquid 
nitrogen and stored at -80 °C. 
 
Organ collection and extract preparation 
Immediately after sampling, 5 mL of blood was transferred into ice-cold (-20 °C), 
deoxygenated aqueous 95 % methanol in a ratio 1:9 (v/v). The urine was weighted and 
transferred into ice-cold, deoxygenated aqueous 95 % methanol at a ratio of 1:9 (w/v). Frozen 
brain was grounded under cryogenic conditions (-196° C) to 5 µm particles in a CryoMill 
(Retsch, Germany), using a single 25 mm i. d. steel ball (30 seconds, 25/sec frequency). The 
pulverized tissue was rapidly transferred (without thawing) into ice-cold, deoxygenated 
aqueous 95 % methanol at a ratio of 1:9 (w/v). trans-Cinnamic acid-d5, as internal standard, 
was dissolved in the aqueous methanol at concentration of 0.1 mg/L for the monitoring of the 
extraction protocol.  
Figure 5.1 Metabolomic worflow for untargeted experiment. 
All samples were extracted with an orbital shaker for 10 min at room temperature. The 
methanol extracts were then centrifuged for 5 min at 3600 rpm at 4 °C, decanted under a 
stream of nitrogen in 50 mL dark glass vessels and stored at -80 °C.  
To assess the most suitable solvent mixture for the Ultra performance liquid chromatography–
quadrupole time-of-flight analysis, different solvent mixtures were evaluated for brain matrix, 
as previously described (Gika & Theodoridis, 2011; G. Theodoridis et al., 2012). The total ion 
current (TIC) chromatograms were used for visual inspection and fast scrutiny of the data. 
Tryptophan peaks in extracted ion chromatograms (XIC) for each solvent mixture(s) were 
subsequently examined in terms of size, shape and retention time (Figure 5.2).  
All samples were filtered through 0.2 lm PVDF filters (Millipore) and injected into a 
UPLC/QTOF-MS system. 
  
Ultra performance liquid chromatography–quadrupole time-of-flight analysis 
Analysis was carried out using a Dionex UPLC, coupled via an electrospray ionization (ESI) 
interface to a LTQ Orbitrap XL QTOF-MS (Thermo Scientific, San Jose, CA USA), 
operating in W-mode and controlled by Masslynx 4.1. with the chromatographic conditions 
summarized in Table 5.1. Mass spectrometric data were collected by separate runs in positive 
and negative ESI mode. The scan cycle started with a full scan mass spectrum (MS) mode at a 
resolving power of 30.000 (with a scan window divided in two scan events: 100-550 m/z, and 
500-1500 m/z). Based on pre-scan information from the full scan MS, a second injection with 
Data Dependant MSn scan (a FullScan Mode as referenced scan event with three scan events 
with MSn as Data Dependent Scan, each at a resolving power of 7500), was performed. 
Table 5.1 Chromatographic and spectrometric conditions. 
HPLC Dionex 3000 Nano HPLC  
Column   Kinetex 2.6 µm C18 100 Å 
Column temperature  4° C 
Injection volume  10 µL 
Eluent flux   0.3 mL/min 
Solvent A   0.1% formic acid in isopropanol 
Solvent B  0.1% formic acid in mQ water 
Solvent C 0.1% formic acid in acetonitrile 
Gradient  
Multistep linear gradient: 
 
 
Urine samples: 
 
Mass spectrometer  LTQ Orbitrap XL QTOF-MS 
Source Voltage 5.00 kV (positive) 3.50 kV (negative) 
Source Current 100.00 µA 
Capillary Voltage 30.00 V 
Tube Lens 110 V 
Mass range 100-550 m/z and 500-1500 m/z 
Capillary Temp 320.00° C 
APCI Vaporizer Temp 0.00° C 
Sheath Gas Flow 35.00 a.u. 
Aux Gas Flow 5.00 a. u. 
Sweep Gas Flow 0.00 a. u. 
 
 
Quality control 
Twenty-two samples of each investigated tissue were randomized before injection. To correct 
for batch effects and to allow the equilibration of the analytical system, a blank solution 
(solvent, 5 µL) was injected every twelve samples. Furthermore, pooled Quality Control (QC) 
samples, prepared from each tissue, were injected several times during the experiment to 
monitor drifts in the analytical pipeline.  
The stability of the retention times, areas and heights was checked in all injections for the 
signal of the internal standard (rosmarinic acid-d7) added to the samples, which was 
considered suitable to check the global stability of the process. The stability was confirmed 
also by injecting a standard mixture of 11 compounds (G. A. Theodoridis et al., 2012) at the 
beginning and at the end of the analyses of each tissue, both in positive and in negative ESI 
mode.  
 
Data Analysis Workflow 
 
MS data acquisition, conversion, and storage  
Raw untargeted metabolomic data were transformed to the open mzXML format by the 
ProteoWizard 2.1.x suite (Holman et al., 2014; Kessner et al., 2008). After conversion, the 
data have been stored and organized as a specific ISA-Tab text file, implemented by the 
cross-platform ISACreator software (Rocca-Serra et al., 2010). All data preprocessing and 
analysis was performed within the R software environment for statistical computing and 
graphics (The R Core Team, 2014). In particular, data import and export, preprocessing and 
visualization were performed with metaMS, a package that implement a pipeline for 
untargeted GC–MS and LC-MS metabolomics (Wehrens et al., 2014). MetaMS is based on 
the open source packages xcms (Smith et al., 2006) and CAMERA (Kuhl et al., 2012). 
 
Data processing  
All runs apart from the solvent and the standard injections were selected. The data with 
retention times lower than 1 min and higher than 21 min were disregarded, annotation was not 
performed. The data were preprocessed with a set of parameters optimized for the specific 
chromatographic and instrumental conditions (Orbitrapstefano.Rdata). 
 
Stastistical analysis 
Several types of scaling method were evaluated, and a total ion current (TIC) normalization 
was performed prior to the multivariate analysis, to account for small differences in the 
efficiency between the different samples within the analytical run. Unsupervised principal 
component analysis (PCA), was used to identify major outliers (removed from further 
analysis).  
Univariate analysis (e.g. Student’s t test, ANOVA) with a multiple testing corrections was 
performed to reduce the inclusion of false discoveries when undertaking the multiple 
comparisons: p-values were corrected using false discovery rate (FDR) adjustments of 
Benjamini-Hochberg (Benjamini & Hochberg, 1995) with FDR < 0.10 or < 0.05.  
Results and discussion 
 
Efficiency of extraction solvent 
The choice of solvent in which metabolites are extracted from tissues plays a crucial role in 
untargeted investigations. In the present study, experiments were performed to evaluate the 
efficiency of various solvent combinations for extracting metabolites from samples of 
complex multicompartment systems (Kim & Verpoorte, 2010) such as the brain. The best 
response was achieved with aqueous methanol (3:7, v/v), which improved the solubility of 
hydrophilic metabolites. Practical issues in the extraction procedure were also considered. 
The formation of emulsions had to be avoided because they were unfavorable for subsequent 
chromatographic analysis and could compromise method repeatability by introducing bias 
(see Figure 5.2 and Table 5.2 for details). The optimum solvent ratios provided richer 
chromatograms with higher levels of information. 
 
  
Figure 5.2 (Previous pages) Efficiency of extraction solvent for brain tissue. Pre-concentration of the brain matrix (1:2, 
1:8) did not bring significant improvement of the signal intensity. Different water content in the final solution does not 
impact compounds for rt > 10 min, with changes only in the relative intensity. Any addition of water after evaporation 
produced deterioration of the matrix and peak shape worsening. For more details see Table 5.2. 
 
Table 5.2 Summary of different solvent ratios. 
TIC MeOH H2O Preconcentration Solution XIC Tryptophan 
A 0.7 0.3 / slightly opaque good peak shape 
B 0.7 0.3 2:1 opaque double peak shape 
C 0.5 0.5 2:1 completely opaque good peak shape 
D 0.7 0.3 15:4 opaque double peak shape 
E 1 / 5:1 clear peak shape fronting 
 
Data preprocessing 
Following data acquisition, the obtained mass spectra were subjected to various data pre-
processing methods, i.e. mathematical operations, in order to facilitate and enhance the 
subsequent data analysis. Data preprocessing by metaMS generated six annotated peak tables. 
Each peak table reports retention time (rt) and mass/charge ratio (mz) value for each feature, 
isotope annotation (isotope), common adducts (adduct), and the group number (pcgroups). 
The latter was obtained by clustering the features considering their retention time and the 
correlation between the extracted ion chromatograms to identify co-eluting ions. As a result of 
this procedure, the features were grouped into groups that are likely to be related to the same 
metabolite. The peak tables generated by metaMS were used as data matrices for further 
statistical analysis. 
Extraction and number of features 
Brain, plasma and urine extracts were compared in terms of the extracted features in ESI+ and 
ESI- mode. The total number of extracted features detected in ESI+ was 2193 in brain, 2417 
in plasma and 4304 in urine. On the other hand, the total number of features detected in ESI- 
was 1140 in brain, 1328 in plasma and 2846 in urine.  
Urine showed the highest number of detected features in both ionization modes. The 
distribution in the space defined by the m/z ratio and chromatographic retention time of the 
experimental features obtained in ESI positive mode, evidenced that most of them were 
generated from highly hydrophilic, polar compounds eluting in the earliest part of the 
chromatogram, as well as hydrophobic metabolites, eluting in the final part of the gradient 
(Figure 5.3).  
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Figure 5.3 Distribution in the space defined by the m/z ratio and chromatographic retention time of the 
experimental features obtained in ESI positive mode for the extracts from blood (A), brain (B), and urine (C) of 
adult male rats. The samples were collected 0.25(); 2(); 15(); 20(); min after intravenous administration of 667 nmol 
cyanidin 3-glucoside. 
Although the number of features does not correlate directly with the number of metabolites, 
it’s considered to be ''proportional'' to metabolites. Ionization process generates several ions 
from the same neutral molecule. In almost all cases, tens of different features in the data 
matrix represented each molecule. This redundancy is typical of a so-called “fat” data matrix, 
in which the number of samples is (much) smaller than the number of variables. 
Consequently, statistical tools used for data reduction had to deal with the multiplicity 
problem, which actually limited the capacity of finding robust and consistent biomarkers. 
 
Quality assessment 
PCA was used to check analytical stability in relation to the biological variability of the 
samples. This type of analysis is commonly applied to multivariate metabolomics datasets in 
which several variables (signals in a mass spectrum arising from metabolites) are processed 
simultaneously for a certain number of samples (Nicholson et al., 1999; Worley & Powers, 
2013). Each variable n (n > 1) can be considered a unique dimension; thus, each sample can 
be represented in n-dimensional space. However, such space is quite difficult to visualize and 
interpret; therefore, PCA reduces the dimensionality via a projection technique so that 
individual samples can be compared in a lower (e.g., two-dimensional) space called a PCA 
score plot. The score plots for the brain, blood, and urine datasets are displayed in Figure 5.4, 
5.5, and 5.6, respectively. The points in the figure show the positions of the various samples 
in the plane of higher variance. On the plot, the separation of the samples obtained at different 
time points after treatment is clearly visible. The averaging of intersample features provided 
evidence of marked inter-individual variability. However, the Quality Controls (QCs) 
constituted a tight cluster in the middle of the “real” samples only in the urine dataset. This 
behavior is an indication of robust analytical reproducibility because it shows that the 
variability due to the analytical platform (the spread of the QC points) is much smaller than 
the biological variability among samples (Franceschi et al., 2014). Accounting for the 
influence of confounding factors, figure 5.7 demonstrates how the integral of the TIC varied 
over the full analytical run of 30 injections (~12 h). As expected, the efficiency of the 
instrument was constant. This plot does not indicate the presence of particularly critical 
injections, which would have required the reinjection of some of the samples.  
 
 
Figure 5.4. Principal components analysis scores plots for blood extract in negative (down) and positive (up) scan 
mode. Different colors are used to identify the different sample classes (time points) and the QCs. 
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Figure 5.5 Principal components analysis scores plots for brain extract in negative (up) and positive (down) scan 
mode. Different colors are used to identify the different sample classes (time points) and the QCs. 
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Figure 5.6 Principal components analysis scores plots for urine extract in negative (down) and positive (up) scan 
mode. Different colors are used to identify the different sample classes (time points) and the QCs. 
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Figure 5.7 Variation of the integral of the TIC over the analytical run for blood (A), brain (B), and urine (C) extracts.
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Univariate and multivariate statistical methods 
We first conducted PCA on each of three complete datasets (brain, plasma, and urine), and 
then tested the significance of any group separation. Several statistical tests were used to 
provide a framework for the interpretation of the untargeted data analysis, which allowed us 
to filter significantly changed features between groups via univariate testing such as a t-test or 
ANOVA with FDR at a level of 5% or 10% correction for multiple testing (Benjamini & 
Hochberg, 1995). A list of the features that passed the various filtering methods is given in 
Table 5.2. 
Initially we compared observations between the first and last time points (0.25–20 min) with 
the Student’s t-test. Correlations were then evaluated using a linear regression model. 
Looking at the slope factor, we undertook a first inspection if we found metabolic variations 
consistent with cyanidin 3-glucoside treatment. We obtained no features for the brain and 
blood dataset in positive/negative scan mode and three features for the urine dataset in 
positive scan mode only. 
However, with this approach we risked losing a physiological hormetic-like response (U-
shaped). Thus, we jointly tested all of the differences between time points (using multivariate 
ANOVA) and then discarded pairs of time points that were not jointly significant before 
applying the FDR. Correlations were then evaluated using a quadratic regression model. In 
this case, we obtained three features from the brain dataset and two from the blood dataset in 
negative scan mode. The features in the urine dataset in positive scan mode numbered 74. 
Discriminating features obtained for the brain, blood, and urine datasets are reported in 
Figures 5.8, 5.9 and 5.10, respectively. At the end of the analysis, the pcgroup of each 
identified feature was examined to identify co-eluting ions. 
Placing statistically significant findings from data analysis into a biological context requires 
the assignment of features to their metabolite identities. The association of the groups of 
obtained features to specific metabolites, commonly referred as annotation, is the biggest 
challenge for untargeted metabolomics experiments. To determine the identity of the features 
of interest, we first searched for the accurate mass of a compound in an online chemical 
structure database. However, a database match denoted only a putative metabolite assignment 
that was impossible to confirm by comparing the retention time and tandem MS data of 
standard compounds to those of the features of interest. On the contrary, the raw data 
supplemented by a set of standardized metadata and organized into a coherent repository were 
made available on the MetaboLights server (Haug et al., 2013) for use in further analysis. 
 
Figure 5.8 Discriminating features identified in brain extracts. 
 
 
 
Figure 5.9 Discriminating feature identified in blood extracts. 
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Figure 5.10 First 3 discriminating features identified in urine extracts. 
 
Conclusions 
The data analysis workflow presented here allowed us to examine the efficacy of different 
imputation methods for finding significantly changed features via multivariate and univariate 
testing. The challenge of correctly reducing a “fat” and redundant data matrix to a 
“manageable” list of features was successfully overcome.  
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Table 5.3 List of discriminating features identified. 
Dataset pcgroup isotopes mz rt 
Brain 1  1.549.282 1.039.905 
36  1.190.235 1.571.006 
38  2.250.609 1.879.433 
    
Blood 41  172.0977 5.89945 
    
Urine 19  1.710.992 0.9208375 
10  1.370.760 0.9692217 
10  4.131.044 10.515.000 
10  1.270.501 10.624.933 
10  4.131.377 10.839.533 
55  1.768.845 11.073.217 
17 [163][M+1]+ 2.461.451 12.161.825 
45  2.750.939 19.560.333 
20 [338][M+1]+ 3.601.130 20.711.917 
20 [338][M]+ 3.591.092 20.716.167 
20  1.800.583 20.720.500 
20 [338][M+2]+ 3.611.052 20.724.417 
67  3.050.624 22.801.917 
58  2.891.096 23.737.667 
11  2.901.127 23.747.000 
11  3.731.063 24.290.583 
37 [122][M]+ 2.240.739 26.518.667 
37 [122][M+1]+ 2.250.772 26.519.833 
37 [122][M+2]+ 2.260.697 26.538.667 
31  1.780.895 28.149.167 
31  1.800.476 28.464.083 
31 [187][M]+ 2.550.797 28.548.833 
31 [187][M+1]+ 2.560.831 28.724.167 
40  4.131.373 31.043.167 
113  4.291.322 32.847.833 
39  3.271.008 38.080.500 
39 [241][M]+ 2.861.107 38.254.417 
39 [241][M+1]+ 2.871.141 38.268.500 
39  3.731.063 38.320.917 
29 [245][M+2]+ 2.911.160 39.357.917 
29 [245][M+1]+ 2.901.126 39.397.750 
29  2.710.989 39.409.250 
29 [245][M]+ 2.891.095 39.536.917 
13  2.831.111 41.355.333 
13 [386][M+2]+ 4.151.338 41.821.000 
13 [386][M+1]+ 4.141.410 41.891.167 
13 [386][M]+ 4.131.374 41.918.833 
13  3.731.249 42.044.500 
13  2.460.907 42.434.333 
13  2.290.642 42.443.333 
13  2.650.641 42.444.000 
13  1.491.072 42.919.500 
13  4.651.410 43.072.250 
13  2.280.689 43.163.833 
1  2.401.545 44.254.167 
1  2.120.740 44.254.167 
1  1.420.320 44.254.333 
1 [440][M]+ 4.792.029 44.254.333 
1 [440][M+1]+ 4.802.064 44.254.333 
1 [151][M+1]+ 2.411.084 44.254.417 
1  1.640.528 44.254.500 
1 [151][M+2]+ 2.421.010 44.254.833 
1  1.520.528 44.257.333 
1 [151][M+3]+ 2.431.042 44.257.750 
1 [80][M]+ 1.940.634 44.258.167 
1  2.421.123 44.268.000 
1  1.250.292 44.277.833 
1  1.940.998 44.277.833 
1 [151][M]+ 2.401.051 44.277.833 
1 [332][M]2+ 3.541.168 44.337.833 
1 [332][M+1]2+ 3.546.187 44.425.833 
1 [42][M]+ 1.660.684 44.426.500 
1  2.380.899 44.438.750 
1 [120][M]+ 2.220.948 44.482.667 
1  1.530.606 44.495.667 
1  2.081.332 44.785.417 
30  4.431.480 46.505.750 
30  2.750.939 46.699.500 
9  3.411.258 47.298.667 
9 [381][M+1]+ 4.071.388 47.317.500 
9 [84][M]+ 1.960.791 47.667.500 
9  4.451.459 47.681.500 
9 [84][M+2]+ 1.980.748 47.694.083 
9 [84][M+1]+ 1.970.809 47.777.833 
9  4.201.143 48.089.500 
9 [409][M]+ 4.471.251 48.132.500 
9 [409][M+1]+ 4.481.287 48.183.500 
16 [392][M+1]+ 4.281.203 48.355.833 
16 [392][M]+ 4.271.167 48.369.917 
124  1.460.599 49.246.167 
124  3.470.365 49.246.750 
59 [38][M+1]+ 1.640.898 49.386.667 
59 [38][M]+ 1.630.865 49.524.833 
59  4.021.151 49.576.167 
21  3.871.042 49.818.500 
21  2.580.795 49.997.667 
21 [289][M]+ 3.170.624 50.069.167 
21  3.621.202 50.091.500 
21 [269][M]2+ 3.051.045 50.174.000 
21 [269][M+2]2+ 3.061.080 50.220.500 
21  1.800.476 50.460.833 
21  4.701.408 50.679.000 
15  4.881.514 51.009.833 
15 [354][M+1]+ 3.731.139 51.169.083 
15 [331][M+1]+ 3.551.041 51.171.833 
15 [331][M]+ 3.541.005 51.241.250 
15 [354][M+2]+ 3.741.076 51.257.000 
15  1.390.448 51.265.750 
15 [185][M+3]+ 2.571.199 51.296.167 
15 [354][M]+ 3.721.111 51.331.167 
15 [185][M+1]+ 2.551.242 51.355.000 
15  1.800.840 51.362.917 
15 [185][M]+ 2.541.208 51.363.167 
15 [185][M+2]+ 2.561.167 51.363.167 
15  3.571.199 51.622.750 
15  4.031.157 51.765.250 
15  3.421.119 51.769.500 
15  4.021.233 51.818.000 
15  2.470.949 51.837.833 
15  2.720.773 51.845.833 
71  3.561.162 51.902.167 
71  4.011.198 51.954.500 
71  1.980.946 52.401.167 
8  3.101.219 52.698.833 
8  2.000.375 52.764.500 
8  2.771.095 52.867.500 
8  2.281.053 52.889.417 
8  4.611.405 53.076.833 
8  4.310.942 53.093.833 
5  2.241.600 53.592.333 
5 [444][M+2]+ 4.851.866 53.592.833 
5 [30][M+1]+ 1.540.568 53.692.833 
5  1.610.420 53.742.667 
5  1.370.419 53.759.833 
5  2.240.859 53.772.750 
5  1.350.263 53.793.000 
5  1.230.262 53.799.167 
5 [60][M+1]+ 1.820.516 53.816.167 
5 [129][M+1]+ 2.271.095 53.821.250 
5 [27][M+1]+ 1.520.609 53.861.167 
5 [30][M]+ 1.530.534 53.876.750 
5 [129][M]+ 2.261.062 53.886.667 
5 [60][M]+ 1.810.483 53.905.167 
5 [58][M+1]+ 1.800.559 53.927.833 
5 [124][M+1]+ 2.251.137 53.927.833 
5 [487][M]+ 5.441.416 53.964.167 
5 [487][M+1]+ 5.451.451 53.964.167 
5 [27][M]+ 1.510.575 54.053.333 
5 [58][M]+ 1.790.525 54.095.333 
6 [123][M+1]+ 2.250.985 54.983.500 
6 [123][M+2]+ 2.260.908 55.154.250 
33  2.421.210 55.365.333 
33  3.851.249 55.582.833 
7  1.220.963 56.676.833 
7  2.351.264 56.799.333 
14 [483][M]+ 5.412.024 57.327.667 
14 [483][M+1]+ 5.422.059 57.331.167 
14  2.331.198 57.334.500 
14 [210][M+1]+ 2.721.023 57.334.500 
14 [210][M]+ 2.710.991 57.379.833 
14  1.500.661 57.382.917 
14 [246][M+2]+ 2.911.162 57.385.833 
14 [153][M]+ 2.431.041 57.402.667 
14  3.470.731 57.402.667 
14 [246][M+1]+ 2.901.127 57.501.167 
14 [246][M]+ 2.891.095 57.517.667 
14  4.651.411 57.858.250 
14  2.671.162 57.945.000 
14  3.241.376 58.426.333 
4 [323][M+2]+ 3.460.945 59.175.833 
4 [323][M]+ 3.440.985 59.205.833 
4 [323][M+3]+ 3.470.979 59.212.667 
4 [61][M]+ 1.810.683 59.793.500 
4 [61][M+1]+ 1.820.714 59.884.000 
4 [61][M+3]+ 1.840.673 59.889.250 
4  1.130.054 59.897.167 
4  1.530.732 59.901.500 
26  2.281.218 60.011.167 
26  2.261.260 60.023.000 
26 [389][M+1]+ 4.171.232 60.064.000 
26  5.461.759 60.524.167 
76  3.220.922 60.986.167 
76  3.671.776 60.997.833 
76  3.221.198 61.013.667 
43 [190][M]+ 2.561.366 61.519.667 
43 [190][M+1]+ 2.571.398 61.523.667 
43 [240][M]+ 2.860.930 61.765.000 
43  4.291.511 61.778.500 
43  4.421.349 61.907.833 
43  4.521.305 61.950.333 
43  5.051.125 61.984.000 
73  4.931.818 62.486.000 
73  2.090.378 62.651.167 
73 [251][M]+ 2.950.747 62.652.833 
73  3.401.325 62.654.500 
73 [251][M+1]+ 2.960.781 62.659.333 
73  3.170.566 62.664.750 
112  3.600.934 63.061.833 
112  1.470.916 63.105.583 
2  3.450.212 63.232.833 
2  5.042.095 63.495.417 
2  2.210.518 63.595.333 
2 [181][M]+ 2.531.005 63.755.500 
2  1.210.885 63.756.000 
2  1.340.963 63.756.000 
2 [40][M+1]+ 1.650.563 63.756.000 
2 [40][M+2]+ 1.660.486 63.756.000 
2 [40][M]+ 1.640.528 63.756.167 
2  2.211.104 63.756.167 
2 [117][M+1]+ 2.221.138 63.756.167 
2  2.231.064 63.756.167 
2  2.231.169 63.756.167 
25  3.760.705 64.648.333 
25  1.650.910 64.650.250 
205  3.211.358 65.203.333 
153  4.741.609 65.575.167 
153  2.411.546 65.737.667 
153  1.780.862 65.764.000 
38  2.395.768 65.950.000 
38  4.781.459 65.950.167 
38 [437][M+1]+ 4.751.907 66.133.167 
38 [231][M+1]+ 2.820.625 66.464.250 
38  2.630.485 66.491.167 
38 [231][M]+ 2.810.591 66.494.667 
44  4.431.663 67.389.167 
44  4.271.166 67.720.667 
44  4.321.042 67.874.500 
44  3.821.250 68.120.833 
44  2.526.028 68.521.500 
36  3.961.685 68.917.667 
36  3.871.040 69.409.167 
36 [180][M+1]+ 2.521.246 69.474.167 
82  3.881.059 69.823.833 
82  2.561.001 69.832.667 
82 [232][M]+ 2.810.954 69.959.333 
82  3.261.533 69.984.333 
82 [232][M+1]+ 2.820.988 69.992.500 
85  3.101.219 71.103.417 
85  2.870.460 71.129.167 
85 [202][M+1]+ 2.660.674 71.137.667 
85 [202][M]+ 2.650.641 71.147.667 
85 [202][M+2]+ 2.670.599 71.163.500 
114  4.561.253 71.945.667 
91  1.930.430 72.213.667 
91  1.350.804 72.582.833 
91  2.430.686 72.739.667 
54  3.220.858 76.216.000 
49  3.591.787 76.606.667 
49 [448][M+1]+ 4.941.853 76.738.167 
49 [448][M+3]+ 4.961.805 76.738.667 
49 [448][M]+ 4.931.821 76.747.667 
49 [448][M+2]+ 4.951.768 76.750.917 
116  2.490.693 77.977.333 
126  4.711.615 78.280.333 
34 [182][M+2]+ 2.550.963 79.187.333 
34 [182][M+1]+ 2.541.039 79.201.833 
34  2.690.955 79.205.833 
34 [182][M]+ 2.531.005 79.282.917 
34  2.350.900 79.369.333 
34  1.640.705 79.497.833 
149  1.711.491 80.427.833 
149  2.790.434 81.322.833 
89  4.100.839 82.198.667 
89  2.341.037 82.744.500 
89  2.950.383 82.791.500 
135 [472][M+1]+ 5.261.575 83.652.250 
135 [472][M]+ 5.251.541 83.715.417 
61  2.810.954 85.447.833 
100 [374][M+1]+ 3.971.081 87.133.000 
100 [374][M]+ 3.961.044 87.157.667 
74  4.651.871 88.661.667 
88 [362][M+1]+ 3.811.949 90.404.917 
88 [362][M]+ 3.801.914 90.409.083 
88  3.851.468 90.473.583 
63  2.710.875 91.708.250 
63  2.941.635 91.716.167 
63 [175][M+1]+ 2.501.089 91.720.500 
63 [175][M]+ 2.491.056 91.721.000 
108  1.230.239 96.435.167 
108 [171][M+1]+ 2.491.226 96.513.667 
108 [171][M]+ 2.481.193 96.623.833 
111  2.670.798 99.831.667 
211  2.330.742 107.392.667 
178  2.971.332 123.604.167 
81  4.523.942 174.139.167 
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Chapter  6. Reactive oxygen species 
detection in aqueous environments with 
SERS-based nanosensors 
 
 
 
 
Chapter Overview 
In this chapter we propose a novel SERS-based nanosensor (NS) for the detection of ROS in 
aqueous environments. The NS was based on gold nanoparticles (AuNPs), a widely used 
substrate due to its ease of preparation and efficient enhancement of Raman signal (Munro et 
al., 1995). NS were obtained by coating citrate-reduced AuNPs with oxidation-sensitive 
reporter molecules. Three SERS active molecules, namely 6-Amino-6'-hydroxy-3H-spiro[2-
benzofuran-1,9'-xanthene]-3,3'(9a'H)-dione (6AF), 1,2-Diamino-9,10-anthraquinone (DAQ), 
and 2,3-Naphthalenediamine (DAN), were used in this work. Various ROS/RNS can induce a 
chemical change in the structure of the molecules adsorbed onto the surface of gold 
nanoparticles (Au-NPs), and hence reflected in SERS fingerprint. The preparation of 6AF-/, 
DAQ-/, and DAN-coated Au nanoparticles (6AF-/, DAQ-/ and DAN-AuNPs), their 
characterization using UV-Vis spectrophotometry and SERS spectroscopy, and their 
applicability as sensors for ROS/RNS detection are reported here. All of them have been 
found to undergo oxidation reaction in buffered aqueous solutions, but only the 6AF-AuNPs 
could be shown to be an efficient SERS sensor, so allowing the measurement of specific 
ROS/RNS under versatile experimental conditions. 
Experimental section 
 
Materials 
Sodium tetrachloroaurate (III) dehydrate (AuCl4- Na︎ 2H2O), sodium citrate tribasic dihydrate 
(Na3C6- H5O7︎ 2H2O), 6-Amino-6'-hydroxy-3H-spiro[2-benzofuran-1,9'-xanthene]-
3,3'(9a'H)-dione (6AF, C20H13NO5), 1,2-Diamino-9,10-anthraquinone (DAQ, 
C14H10N2O2), 2,3-Naphthalenediamine (DAN, C10H2N2), 1,4,7,10,13,16-
Hexaoxacyclooctadecane (18-Crown-6, C12H24O6), potassium superoxide (KO2), 2,2-
Azobis(2-amidinopropane) dihydrochloride (ABAP, [=NC(CH3)2C(=NH)NH2]2·2HCl), 
hydrogen peroxide (H2O2), ethanol (EtOH) and all solvents used were purchased from 
Sigma-Aldrich and used without further purification. Peroxynitrous acid, sodium salt (ONO2 
• Na) in 0.3 M NaOH solution was purchased from Cayman Chemicals (Ann Arbor, MI). 
MilliQ water was used for the preparation of all solutions.  
Hank's balanced salt solution (HBSS) was purchased from EuroClone (Wetherby West, 
Yorkshire, UK). Dulbecco's Modified Eagle's Medium (DMEM), and Roswell Park Memorial 
Institute medium (RPMI) 1640, were obtained from Gibco, Invitrogen (Paisley, Scotland, 
UK). Phosphate buffered saline (PBS) was prepared as following: 6.03 mM Na2HPO4, 3.91 
mM NaH2PO4 and 139 mM NaCl (Carlo Erba, Milan, Italy) were dissolved in MilliQ water 
Figure 6.1 Schematic diagram of the SERS-based nanosensor for sensing O2•−. 
and pH was adjusted to 7.4 with HCl. CaF2 microscope slides were purchased from Crystal 
GmbH (Berlin, Germany).  
Raman Instrumentation 
Spectroscopic measurements were done using an InVia Raman system (Renishaw, Wotton-
under-Edge, UK). The sample was deposited, as pure powder or in the form of a 50 µL drop, 
on a UV-grade CaF2 microscope slide and put under the Raman microscope. The laser source 
(785 nm, 200 mW, diode laser) was focused on the sample, with a 10x objective (N.A. 0.25), 
and the Raman spectrum was collected with a 10s exposure. 
 
Cit-AuNPs preparation 
The synthesis was performed using the Turkevich/Frens method (Turkevich et al., 1951), with 
slight modifications. Briefly, in a 250 mL round-bottom flask equipped with a condenser, 90 
mL of mQ water was brought to boil and 10 mL of 0.1% HAuCl4 was added under vigorous 
stirring for 1 minute. Rapid addition of 4 mL of 1% sodium citrate solution to the stirred gold 
chloride solution resulted in a color switch from pale yellow to dark wine red. The color 
switch occurred over several minutes. The solution was maintained for 30 minutes at boiling 
temperature and then removed from the heating bath. Stirring was continued until the solution 
reached room temperature. This pure solution of citrate-capped gold nanoparticles (Cit-
AuNPs) was then used for the further functionalization.  
 
Preparation of functionalized-AuNPs 
 
Preparation of Au-nanoparticles coated with 6-Amino-6'-hydroxy-3H-spiro[2-benzofuran-
1,9'-xanthene]-3,3'(9a'H)-dione (6AF) 
A 6AF stock solution was prepared dissolving 6AF in dehydrated methanol to obtain a final 
concentration of 3 mM. 6AF solutions were prepared by properly diluting the stock solution 
with mQ water, or phosphate buffered solution (PBS, pH 7.4) to achieve the desired final 
concentration (300 nM - 300 µM). Extreme care was taken to avoid 6AF photo-degradation 
upon light exposure: all dilutions were done in a dark room with red safelight illumination.  
Then, 50 mL of the 6AF solution were added to 50 mL of Cit-AgNPs previously diluted 1:25 
with mQ water. To remove 6AF excess, the mixture was centrifuged in 1.5 mL polypropylene 
eppendorf tubes at 6708 x g for 20 minutes, the supernatant was removed and fresh mQ water 
was added. This washing procedure was repeated 3 times.  
 
Preparation of Au-nanoparticles coated with 1,2-Diamino-9,10-anthraquinone (DAQ) 
A DAQ stock solution was prepared dissolving DAQ in in anhydrous dimethyl sulfoxide to 
obtain a final concentration of 5 mM. DAQ solutions were prepared by properly diluting the 
stock solution with mQ water, or phosphate buffered solution (PBS, pH 7.4) to achieve the 
desired final concentration (500 nM - 500 µM). Extreme care was taken to avoid DAQ photo-
degradation upon light exposure: all dilutions were done in a dark room with red safelight 
illumination.  
Then, 50 mL of the DAQ solution were added to 50 mL of Cit-AgNPs previously diluted 1:25 
with mQ water. In order to remove DAQ excess, the mixture was centrifuged in 1.5 mL 
polypropylene eppendorf tubes at 6708 x g for 20 minutes, the supernatant was removed and 
fresh mQ water was added. This washing procedure was repeated 3 times.  
 
Preparation of Au-nanoparticles coated with 1,2-Naphthalenediamine (DAN) 
A DAN stock solution was prepared dissolving 6AF in in anhydrous dimethyl sulfoxide to 
obtain a final concentration of 7 mM. DAN solutions were prepared by properly diluting the 
stock solution with mQ water, or phosphate buffered solution (PBS, pH 7.4) to achieve the 
desired final concentration (700 nM - 700 µM). Extreme care was taken to avoid DAN photo-
degradation upon light exposure: all dilutions were done in a dark room with red safelight 
illumination.  
Then, 50 mL of the DAN solution were added to 50 mL of Cit-AgNPs previously diluted 1:25 
with mQ water. In order to remove DAN excess, the mixture was centrifuged in 1.5 mL 
polypropylene eppendorf tubes at 6708 x g for 20 minutes, the supernatant was removed and 
fresh mQ water was added. This washing procedure was repeated 3 times. 
 
Nanoparticles characterization 
To check repeatability between different preparations, all colloids were characterized by UV–
Visible absorption spectroscopy, using a Lambda 20bio UV–Vis spectrometer (Perkin- Elmer, 
Monza, Italy). UV-vis absorption spectra were acquired between 350 nm and 700 nm. 
Samples were prepared by diluting 10 times the citrate-reduced gold nanoparticles stock 
solution with mQ water in a 3 mL cuvette.  
To check coating stability against aggregation in different physiological buffer, UV-vis 
absorption spectra were recorded on a Synergy H1 – Hybrid Multi-Detection Reader between 
350 nm and 700 nm. Samples were prepared by diluting 10 times the functionalized-AuNPs 
solution with mQ water, PBS, HBSS, respectively, in a 96-well microplate. 
 
Measurement for ROS specificity and sensitivity 
The response of the probe was measured immediately after treatment with different 
concentrations of the appropriate ROS or RNS at room temperature. In each case, 5 µL of 
ROS/RNS (details are explained below) were added to 45 µL of 6AF-/DAQ-/ or DAN-AuNP 
solution. The final oxidant concentrations were between 5 nM and 5 µM except for H2O2 (5 
nM - 500 µM). All experiments were performed in quadruplicate using the 6AF-/DAQ-
/DAN- AuNPs in mQ water and in PBS at 14.4 µM (6AF), 210 µM (DAQ), or 350 µM 
(DAN) concentration. Because of the probes' pH sensitivity, the same experiments were 
repeated with pure 0.3 M NaOH to confirm that the observed responses were from the oxidant 
species and not from basic pH. This change was then subtracted from that induced by 
ROS/RNS.  
 
Generation of ROS/RNS 
Hydrogen Peroxide (H2O2)  
A 30% (w/w) hydrogen peroxide solution was used as received without further purification. 
From this solution a 0.1 M stock solution was prepared in water. This solution was prepared 
immediately prior to use and added to the f-AuNPs solutions to give the desired final H2O2 
concentrations (5 nM - 500 µM).  
 
Generation of alkyl peroxyl radical (ROO•)  
Following Setsukinai's method (Setsukinai et al., 2003), ROO• was generated by thermolysis 
of 2,2-Azobis(2-amidinopropane)dihydrochloride (ABAP), in the solution, under elevated 
temperature (37° C). The estimated ROO• concentration was about 5 nM - 5 µM 
 
Superoxide anion (O2•-) 
According to the method of Valentine et al. (Valentine & Curtis, 1975) O2•- was generated 
chemically, using ionization of potassium superoxide (KO2) in aqueous solution. Briefly, 60 
mg of 18-Crown-6 were dissolved in 10 mL dry DMSO and then 7 mg of KO2 were quickly 
introduced into the flask using a syringe to avoid contact with air humidity. The mixture of 
reagents was stirred with a Teflon-coated magnetic stirring bar for 1 h to give a pale yellow 
solution of 10 mmol/L O2•-. The O2•- concentrated solution could be stored at 0° C for weeks 
without major decomposition. Superoxide anion concentration was determined by UV 
spectrometry at 250 nm (ε=2686 M ︎ -1cm︎ -1). The appropriate dilution of the stock solution 
was made to give the desired final superoxide anion concentration (5 nM - 5 µM).  
 
Peroxynitrite (ONOO•-) 
The peroxynitrite stock solution (0.3 M NaOH) was diluted 100 folds in 0.3 M NaOH 
solution, kept in dry ice and melted for use immediately before the experiment. The actual 
concentration of peroxynitrite was measured by UV spectrometry at 302 nm (ε=1670 M-1cm-
1), before using it in any experiments. The appropriate dilution of the stock solution was 
made to give the desired final peroxynitrite concentrations (0.5 - 10 µM) 
 
Data Processing 
Data were acquired using the software WiRE 3.2 (Renishaw). All data preprocessing and 
analysis was performed within the R software environment for statistical computing and 
graphics (The R Core Team, 2014). In particular, data import and export, preprocessing and 
visualization were performed with the hyperSpec package (Beleites & Sergo, 2014) for R, 
along with the ggplot2 package (Ginestet, 2011) for graphical display.  
The preprocessing consisted of three steps: i) cosmic rays identification and removal, ii) 
baseline correction iii) smoothing interpolation and intensity vector-normalization. For the 
baseline correction, smoothing splines were automatically fitted through the supporting points 
of the whole spectral range and then subtracted from each spectrum of the dataset using 
function spc.rubberband, and peak picking was performed using detectPeaks from 
package MALDIquant (Gibb & Strimmer, 2012). 
For O2•-quantification, the intensity at the maximum of the 680 cm-1 band of the 6AF SERS 
spectrum was chosen for calibration purposes. The calibration curve, the 95% confidence 
interval for the calibration, the limit of detection (LOD) and the limit of quantification (LOQ) 
were calculated using chemCal (Ranke, 2014). The use of weighted regression for calibration 
was considered and checked, but it was found not necessary, as the standard deviation of 
SERS intensity was not increasing with concentration in the interval used for calibration.  
Results and discussion 
In SERS, the laser irradiation of gold nanoparticles can induce localized surface plasmon 
resonances (SPRs) at a nanostructured surface, which generates enhanced electromagnetic 
fields. If molecules are brought into close proximity to such nanoparticles (e.g., via 
adsorption), a large enhancement of the Raman scattering signal can be observed.  
The molecular structure of solid 6-amino-6′-hydroxy-3H-spiro[2-benzofuran-1,9′-xanthene]-
3,3′(9a′H)-dione (6AF), 1,2-diamino-9,10-anthraquinone (DAQ), and 2,3-naphthalenediamine 
(DAN) are presented in Figure 2, and their Raman spectra at a 785-nm excitation wavelength 
appear Figures 3, 4, and 5, respectively. Raman spectra were also acquired at 514 nm (data 
not shown), at which a strong fluorescence background was recorded as might be expected 
considering the intense color of the aqueous solutions of 6AF, DAQ, and DAN. SERS 
characterizations of 6AF, DAQ, and DAN were obtained under different experimental 
settings with various outcomes.  
Keeping in mind our final goal of ROS/RNS intracellular detection, we selected probes that 
are best excited in the near-infrared region (785 nm) to reduce the native fluorescence 
background and take advantage of this particularly convenient feature for studying biological 
Figure 6.2 Structures of the three probes. 
specimens (i.e., low autofluorescence of proteins, robust tissue penetration) (Weissleder, 
2001). 
To probe our proposed mechanism for ROS/RNS detection, we used Raman spectroscopy to 
characterize the reporter molecules on gold nanoparticle (AuNP) surfaces. Raman 
spectroscopy can characterize the vibrational modes of individual bonds and offers insight 
into chemical structure. Its signals were easily detected in our experiments owing to the 
surface-enhanced Raman scattering by molecules on the plasmonic gold surfaces. 
 
 
Figure 6.3 SERS of 6AF solution in PBS. 
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 Figure 6.4 SERS of DAQ solution in PBS 
 
 
Figure 6.5 SERS of DAN solution in PBS. 
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Characterization 
AuNPs exhibit surface plasmons sensitive to the size, coating, and polydispersity of AuNPs in 
solution (Eustis & El-Sayed, 2006; Glomm, 2005). Hence, some information about AuNPs 
can be obtained by examining the SPR peak present on their absorption spectra. 
Citrate AuNPs had an absorption maximum at 535 nm, which indicated that the average 
diameter of the nanoparticles was approximately 50 nm, consistent with previously reported 
values (He et al., 2005). This estimation, obtained using the ratio Aλmax/Aλ450, applied only to 
AuNPs coated with citrate, and therefore could not be used for 6AF-, DAQ-, or DAN-coated 
AuNPs. However, the SPR peak of the latter nanoparticles showed a slight shift with respect 
to those of the citrate-reduced nanoparticles, so the size of 6AF-, DAQ-, or DAN-coated 
AuNPs was interpreted to have changed during the ligand-exchange reaction. This assumption 
was checked with subsequent SERS experiments. 
 
Ligand exchange 
The stabilization of AuNPs originates from Au/ligand interaction at the gold particle surface. 
Citrate is one of the weakest ligands, providing only limited stability to the nanoparticles. On 
the contrary, the interaction at the AuNP surface is increasingly stronger with phosphine, 
amine, and thiol functions (Leff et al., 1996). 
Because 6AF, DAQ, and DAN contain a primary amine, they were expected to produce 
relatively stable AuNPs via direct interaction of their amino groups with AuNP surface atoms. 
Thus, no modification of the ligands was required. Owing to their stronger interaction 
(compared with that of citrate) with gold, the amine groups of 6AF, DAQ, and DAN readily 
displaced citrate from the surface of previously prepared citrate-reduced AuNPs.  
To determine the ligand concentration yielding the best SERS signal, we collected a series of 
SERS spectra for various concentrations of the three coating agents and obtained curves 
depicting the intensity of the band with the highest signal in the SERS spectrum as a function 
of ligand concentration. The characteristic vibrational modes of each ligand began to appear 
and increase in intensity as a consequence of the increasing extent of AuNP coating. 
The 6AF SERS intensities at 1182 cm-1 as a function of 6AF concentration are reported in 
Figure 5A. The 6AF curve has a slope factor of 1.718 at concentrations below 10-5 M. At high 
concentrations, the working curve approaches a limiting value, presumably corresponding to 
surface saturation. Above this value, large but less reproducible SERS signal intensities were 
observed. 
The DAQ SERS intensities at 1282 cm-1 as a function of DAQ concentration are reported in 
Figure 5B. As shown in the figure, the curve is very steep. The DAN SERS intensities at 834 
cm-1 as a function of DAN concentration are reported in Figure 5C. The intensity did not vary 
appreciably as a function of DAQ and DAN concentrations, and the intensity values showed 
large dispersions. 
 
 
 
Figure 6.6 A. Concentration dependence of the 6AF 1182 SERS intensity. B. Concentration dependence of the DAQ 1282 
SERS intensity. C. Concentration dependence of the DAN 1471 SERS intensity. Each data point represents the average 
intensity of the characteristic peak from four spectra. The standard deviation is shown by the error bars (n=4). 
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Specificity and sensitivity of ROS detection  
To evaluate oxidation-dependent changes in vibrational modes, we incubated 6AF-, DAQ-, 
and DAN-AuNPs with various biologically relevant reactive species including, O2•-, hydrogen 
peroxide, ABAP (for alkyl peroxyl radical [ROO•] and peroxynitrite [ONOO•-]). All of these 
reporter molecules underwent oxidation reactions in buffered aqueous solutions, which 
changed their structures and were in turn reflected in the specific spectral differences shown 
in Figures 6 and 7.  
Repeatable concentration-dependent changes were identified only in the 6AF SERS spectrum 
after the addition of O2•-, which revealed the sensibility of the nanosensor (NS) for the 
superoxide anion radical. Thus, to verify the feasibility of this method for quantitative 
analysis, we collected a series of SERS spectra only for O2•- at various concentrations and 
constructed a calibration curve (i.e., SERS intensity as a function of concentration). The 
maximum intensity of the 680 cm-1 band of the 6AF SERS spectrum was chosen for 
calibration purposes. The concentration-dependent calibration curves for the in vitro detection 
efficiency of 6AF-AuNPs for various ROS/RNS are presented in Figure 8.  
The lowest O2•- concentration measured was 1 nM, which is on the same order of magnitude 
as that of the lowest concentration previously reported in results obtained with other 
techniques (Woolley et al., 2013). For concentrations between 1 nM and 1 µM, the correlation 
between spectrum intensity and superoxide anion radical concentration was linear (Figure 8), 
with a coefficient of determination (R2) of 0.9935. For concentrations lower than 1 nM, the 
spectrum showed no O2•- vibrational bands. The limit of detection (the lowest quantity of 
analyte that can be distinguished from a blank value within a stated confidence limit) and 
limit of quantification (the lowest amount of analyte in a sample that can be quantitatively 
determined with suitable precision and accuracy) calculated from the calibration curve were 
103 nM and 229 nM, respectively.  
 
 
 
Figure 6.7 Representative SERS spectra observed for 6AF-AuNPs under different redox conditions. A. ABAP; B. 
ONOO; C. O2*-; D H2O2. 
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Figure 6.8 Representative SERS spectra observed for DAQ-/ and DAN-AuNPs under different redox conditions. A. 
O2*-; B. H2O2; C. ONOO-. 
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Figure 6.9 Calibration curve on a log-log scale of 680cm-1 band peak intensity vs. O2•-concentrations. The solid line is 
the linear fitting line, with the 95 % confidence interval for the calibration (gray shadow). 
 
Stability in physiological buffer 
Keeping in mind our final goal of ROS/RNS intracellular detection using the SERS-based 
NS, we tested their stability in several physiological buffered solutions and cell culture media. 
6AF-capped gold nanoparticles showed no sign of aggregation, even after few hours, 
differently from what seen with cit-AuNPs. This result confirms the exchange of citrate with 
6AF and opens the possibility of using the NS for cellular applications. Table1 report the 
absorption maximum of 6AF-AuNPs recorded over prolonged periods of time in mQ water, 
PBS, HBSS, DMEM and RPMI, respectively. 
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Table 6.1 Absorption maximum of 6AF-AuNPs over prolonged periods of time. 
 mQ water PBS HBSS DMEM RPMI 
10 min 560 nm 588 nm 558 nm 588 nm 588 nm 
5hour 560 nm 560 nm 560 nm 560 nm 560 nm 
10hour 560 nm 560 nm 560 nm 560 nm 560 nm 
24hour 560 nm 560 nm 560 nm 560 nm 560 nm 
72 hour 560 nm 560 nm 560 nm 560 nm 560 nm 
 
 
Conclusions 
6AF-coated AuNPs were prepared, and consistent results of SERS analysis showed that they 
exhibited selective and concentration-dependent signals after exposure to for O2•-. We 
concluded that the detection sensitivity of the SERS-based NS for O2•- had values comparable 
to those obtained with commonly used spectrophotometric methods. Furthermore, 6AF-
AuNPs exhibited good stability in physiological buffered solutions and cell culture media. 
These results open the possibility of using these SERS-based NSs to study the production of 
ROS inside single living cells. Furthermore, a refinement of this method may allow for the 
multimodal analysis of a complex array of ROS/RNS. The potential for studying the dynamic 
relations between, for instance, superoxide and hydrogen peroxide, would greatly advance 
knowledge of redox dynamics.  
 
Bibliographic references 
 
Beleites, C., & Sergo, V. (2014). HyperSpec: a package to handle hyperspectral data sets in R. 
R package version 0.98-20140523.  
Eustis, S., & El-Sayed, M. A. (2006). Why gold nanoparticles are more precious than pretty 
gold: Noble metal surface plasmon resonance and its enhancement of the radiative and 
nonradiative properties of nanocrystals of different shapes. Chem Soc Rev, 35(3), 209. 
doi: 10.1039/b514191e 
Gibb, S., & Strimmer, K. (2012). MALDIquant: a versatile R package for the analysis of mass 
spectrometry data. Bioinformatics, 28(17), 2270-2271. doi: Doi 
10.1093/Bioinformatics/Bts447 
Ginestet, C. (2011). ggplot2: Elegant Graphics for Data Analysis. Journal of the Royal 
Statistical Society Series a-Statistics in Society, 174, 245-245. doi: Doi 
10.1111/J.1467-985x.2010.00676_9.X 
Glomm, W. R. (2005). Functionalized gold nanoparticles for applications in 
bionanotechnology. Journal of Dispersion Science and Technology, 26(3), 389-414. 
doi: Doi 10.1081/Dis-200052457 
He, Y. Q., Liu, S. P., Kong, L., & Liu, Z. F. (2005). A study on the sizes and concentrations 
of gold nanoparticles by spectra of absorption, resonance Rayleigh scattering and 
resonance non-linear scattering. Spectrochimica Acta Part a-Molecular and 
Biomolecular Spectroscopy, 61(13-14), 2861-2866. doi: Doi 
10.1016/J.Saa.2004.10.035 
Leff, D. V., Brandt, L., & Heath, J. R. (1996). Synthesis and characterization of hydrophobic, 
organically-soluble gold nanocrystals functionalized with primary amines. Langmuir, 
12(20), 4723-4730. doi: Doi 10.1021/La960445u 
Munro, C. H., Smith, W. E., Garner, M., Clarkson, J., & White, P. C. (1995). Characterization 
of the Surface of a Citrate-Reduced Colloid Optimized for Use as a Substrate for 
Surface-Enhanced Resonance Raman Scattering. Langmuir, 11(10), 3712-3720. doi: 
10.1021/la00010a021 
Ranke, J. (2014). chemCal: Calibration functions for analytical chemistry. R package version 
0.1-34.  
Setsukinai, K., Urano, Y., Kakinuma, K., Majima, H. J., & Nagano, T. (2003). Development 
of novel fluorescence probes that can reliably detect reactive oxygen species and 
distinguish specific species. Journal of Biological Chemistry, 278(5), 3170-3175. doi: 
Doi 10.1074/Jbc.M209264200 
The R Core Team. (2014). R: A Language and Environment for Statistical Computing. 
Vienna, Austria: R Foundation for Statistical Computing. 
Turkevich, J., Stevenson, P. C., & Hillier, J. (1951). A study of the nucleation and growth 
processes in the synthesis of colloidal gold. [10.1039/DF9511100055]. Discussions of 
the Faraday Society, 11(0), 55-75. doi: 10.1039/DF9511100055 
Valentine, J. S., & Curtis, A. B. (1975). A convenient preparation of solutions of superoxide 
anion and the reaction of superoxide anion with a copper (II) complex. Journal of the 
American Chemical Society, 97(1), 224-226. doi: 10.1021/ja00834a058 
Weissleder, R. (2001). A clearer vision for in vivo imaging. Nature Biotechnology, 19(4), 
316-317. doi: Doi 10.1038/86684 
Woolley, J. F., Stanicka, J., & Cotter, T. G. (2013). Recent advances in reactive oxygen 
species measurement in biological systems. Trends in Biochemical Sciences, 38(11), 
556-565. doi: 10.1016/j.tibs.2013.08.009 
 
 
 
 
 
 
 
 
 
Chapter  7. Cellular response and sensor 
development 
 
 
 
 
 
 
 
 
Chapter overview 
In chapter 7 the SERS-based nanosensor (NS) have been further refined for SERS-mapping 
technique with the ultimate goal to enable real-time intracellular observations of ROS in 
living cells. Nanoparticle Tracking Analysis and TEM were performed to characterize the 
dimensions and the cell distribution of the NS. The biocompatibility was assessed in different 
cell lines and, finally, a method for monitoring differences in the presence of ROS/RNS in 
living cells was described.  
Experimental section 
 
Materials 
Sodium tetrachloroaurate (III) dehydrate (AuCl4-Na︎ 2H2O), sodium citrate tribasic dihydrate 
(Na3C6- H5O7︎ 2H2O), Thionyl chloride (SOCl2), 3-mercaptopropionic acid (3-MPA, 
C3H6O2S), 6-Amino-6’-hydroxy-3H-spiro[2-benzofuran-1,9’-xanthene]-3,3’(9a’H)-dione 
(6AF, C20H13NO5), 2,2-Azobis(2-amidinopropane) dihydrochloride (ABAP, 
[=NC(CH3)2C(=NH)NH2]2·2HCl), ethanol (EtOH), and all solvents used were purchased 
from Sigma-Aldrich and used without further purification. Dulbecco’s Modified Eagle’s 
Medium (DMEM), Roswell Park Memorial Institute medium (RPMI) 1640, AlamarBlue® 
and all cell culture reagents were obtained from Gibco, Invitrogen (Paisley, Scotland, UK). 
HEPES-buffered Tyrode’s solution (HBTS) was prepared as follow: NaCl, 150 mM; glucose, 
10 nM; HEPES, 10 mM; KCl, 4.0 mM; MgCl2, 1.0 mM; CaCl2, 1.0 mM (purchased from 
Sigma-Aldrich) were dissolved in MilliQ water and pH was adjusted to 7.4 with NaOH. 
Milli-Q water was used for the preparation of all solutions. CaF2 microscope slides were 
purchased from Crystal GmbH (Berlin, Germany).  
Figure 7.1 Schematic diagram of the SERS-based nanosensor development workflow for ROS sensing in living 
cells. 
Cit-AuNPs preparation 
The synthesis was performed using the Turkevich/Frens method (Turkevich et al., 1951), with 
slight modifications. Briefly, in a 250 mL round-bottom flask equipped with a condenser, 90 
mL of mQ ultrapure water was brought to boil and 10 mL of 0.1% HAuCl4 was added under 
vigorous stirring for 1 minute. Rapid addition of 4 mL of 1% sodium citrate solution to the 
vigorously stirred gold chloride solution resulted in a color change from pale yellow to dark 
wine red. The color change occurred over several minutes. The solution was maintained for 
30 minutes at boiling temperature and then removed from the heating bath. Stirring was 
continued until the solution reached room temperature. Before the reduction process all 
glassware was cleaned using concentrated HNO3 and then chromic acid (2.77 g K2Cr2O7 in 
100 mL H2SO4), and carefully rinsed with Milli-Q water.  
 
Preparation of Au-nanoparticles coated with 6-Amino-6’-hydroxy-3H-spiro[2-
benzofuran-1,9’-xanthene]-3,3’(9a’H)-dione (6AF) 
30 µM 6AF aqueous solution was prepared. Then, under vigorous stirring, 50 mL of the 6AF 
solution were added to 50 mL of Cit-AuNPs previously diluted 1:10 with Milli- Q water. In 
order to remove the coating agent excess, the two mixtures were centrifuged in 1.5 mL 
polypropylene eppendorf tubes at 6708 x g for 20 minutes, the supernatant was removed, and 
fresh Milli-Q water was added. This washing procedure was repeated 3 times. The resulting 
coated-nanoparticles dispersion is stable against aggregation up to 72 h. 
Before their use for SERS experiments, the stock dispersion of coated nanoparticles was 
pelleted by centrifugation and removal from each eppendorf tube of 1.3 mL of the supernatant 
with a micropipette, resulting in a concentrated aqueous dispersion of coated nanoparticles.  
 
Nanoparticles characterization 
 
Spectroscopic measurements 
UV-vis absorption spectra were recorded on a SynergyTM H1 – Hybrid Multi-Detection 
Reader between 350 nm and 700 nm. Samples were prepared by diluting 10 times the 
functionalized-AuNPs stock solution with different buffers in a 96-well microplate. 
 
Nanoparticle-tracking Analysis 
All samples were diluted hundredfold by mQ water immediately before starting Nanoparticles 
Tracking Analysis (NTA). Measurements were performed under trigger mode with a 
NanoSight LM10 Nanoparticle Analysis System (NanoSight, Amesbury UK), equipped with 
a scattering cell with red laser (approx. 40 mW at lambda = 638 nm). NanoSight software 
version NTA 1.5 was used for data accumulation and analysis. The samples were injected into 
the sample chamber with 2.5 mL sterile syringes (SD Plastidek, Spain) until the liquid 
reached the tip of the nozzle. Data was recorded using a 20× objective and 60-second video 
clips, with manual shutter and gain adjustments, but the parameters were kept at the same for 
all comparison samples. Three video measurements were conducted for each sample to obtain 
the mean size of the nanoparticles and the associated standard deviation. All measurements 
were performed at room temperature.  
The Stokes–Einstein equation was used to calculate the sphere-equivalent hydrodynamic 
diameter (d, m) from the measured diffusion coefficient (D, m2 s−1): 
   
where k is the Boltzmann constant (J K−1 ), ︎  is the solvent viscosity (kg s−1 m−1) and T is 
the absolute temperature (K).  
 
Raman Instrumentation 
SERS maps were collected using an InVia Raman microscope (Renishaw plc, Wotton-under-
Edge, UK) equipped with high-power near infrared diode laser (Renishaw plc, and Toptica 
Photonics AG, Germany) delivering between 90 and 120 mW of laser power at the sample.  
The CaF2 slide supporting the samples was mounted on a ProScan II motorized stage (Prior, 
Cambridge, UK) under the microscope.  
A thermoelectrically cooled charge coupled device (CCD) camera was used for detection. 
Spectra of a silicon reference sample (SigmaAldrich, UK) and a neon light source (Renishaw 
plc, UK) were taken to calibrate the wavenumber scale. Single spectra were obtained in the 
600– 1700 cm-1
 
region and consist of 1019 data points each. Maps were taken as previously 
reported (Bonifacio et al., 2010). Briefly, a manually selected region, corresponding to a 
single cell, was mapped with steps of 1 µm, each spectrum of the map was obtained in 0.3 s 
d = kT3πηD
upon excitation with a 735 nm laser, in the 600–1800 cm-1
 
region and consisted of 1272 data 
points. The quantity of spectra for each map varied dependent on the size of cells. 
 
Cell culture 
The SH-SY5Y human neuroblastoma cell line was obtained from the American Type Culture 
Collection (Manassas, VA). Cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 1% (v/v) 
L-glutamine, 0.05 mg/mL penicillin, and 0.05 mg/mL streptomycin and were maintained at 
37 °C with 95% humidified air and 5% CO2. Cells in culture dishes were used for 
experiments after reaching 80% confluence. 
C2C12 mouse adherent myoblasts were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with heat-inactivated 10% fetal bovine serum (FBS), 2mM L-
glutamine, 0.05 mg/mL penicillin, and 0.05 mg/mL streptomycin, 0.5% anti-mycoplasm and 
25 mM Hepes, and were maintained at 37 °C with 95% humidified air and 5% CO2. 
Human endothelial-like immortalized cells (EA.hy926) were cultured in DMEM 
supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), 1% (v/v) L-glutamine, 
0.05 mg/mL penicillin, and 0.05 mg/mL streptomycin. Cultures and were maintained at 37 °C 
with 95% humidified air and 5% CO2.  
CRL-2278 RAW 264.7 gamma NO(-) murine monocytic/macrophagic cell line was 
purchased from American Type Culture Collection (ATCC, Rockville, MD). CRL-2278 
RAW 264.7 gamma NO(-)cells were cultured in a 24-well plate at a density of 1 × 105 
cells/mL in RPMI-1640 medium with 2 mM L-glutamine and modified to a final 
concentration of 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, 10 mM Hepes, 1 mM sodium 
piruvate, and 10% (v/v) fetal bovine serum (FBS). 
 
Toxicity Assay 
The cytotoxicity of various concentrations of 6AF-AuNPs was evaluated using AlamarBlue® 
(Invitrogen) assay, according to the manufacturer’s suggestions. Viable cells convert the cell 
permeable nonfluorescent oxidized compound resazurin to the highly fluorescent- reduced 
resorufin, which is an indicator of cellular metabolic activity. 
This assay is commonly used to determine the extent of cell viability in cultures after various 
treatments (Rampersad, 2012). Briefly, cells were grown in a 96-well plate in 100 µL of 
DMEM supplemented with FBS. After 24 h seeding, cells were incubated with various 
concentrations (from 2 nM to 200 µM) of 6AF-modified gold probes for 44 h, and cell 
viability assay was carried out. After treatments, the assay was performed by replacing the 
culture media with a 10% AlamarBlue solution in DMEM. Reduction of AlamarBlue was 
determined spectrofluorometrically after 3-4 h. (excitation 440 nm, emission 485 nm). The 
untreated cells were used as a positive control (i.e., 100% viable), and all values from the 
experiment were correlated with this set of data. The results were analyzed either by one-way 
or two-way ANOVA followed by Bonferroni’s multiple comparison tests. 
 
Cellular Uptake 
Cellular uptake was mainly analyzed by transmission electron microscopy (TEM). In TEM, 
an image is generated from the electrons beam transmitted through the specimen after the 
interactions between the electrons and specimen (Hawkes, 1985). This technique enables one 
to verify fine structures as small as an atom owing to the small wavelength of electrons. For 
TEM analysis cells were grown on coverslips under the same conditions as for Raman 
spectroscopy. Briefly, cells were grown in a 6-well tissue culture plate at a concentration of 
4.4 × 106 and were incubated overnight with 6AF-AuNPs (5.0 x 108 particles/mL) in FBS-
free media to allow uptake of the nanosensors. After a brief rinse in PBS, cells attached to a 
glass surface were fixed with 2.5% glutaraldehyde in 0.1M phosphate buffer, pH 7.3, for 
10min at room temperature, and then for 20min at 41C. Cells were then rinsed in 0.1 M PBS, 
pH 7.3, post fixed with 1% osmium tetroxide in the same buffer for 1h at 4° C, dehydrated in 
ascending alcohols, and then treated with propylene oxide. After embedding in Araldite 
(Electron Microscopy Sciences, Ft. Washington, PA, USA), ultrathin sections of the cell were 
cut with a Reichert OM ultramicrotome. Sections were stained with uranyl and lead citrate, 
and then examined with an electron microscope Jeol 100S (JEOL, Peabody, MA, USA). The 
image-analysis tool JMicroVision version 1.2.7 (www. jmicrovision.com) was used for 
analysis of TEM images (Roduit N. JMicroVision: image analysis toolbox for measuring and 
quantifying components of high-definition images. Version 1.2.7. 2008. Available from: 
http://www.jmicrovision.com. Accessed June 16, 2014). 
 
Intracellular SERS experiments 
All SERS mapping experiments were made using living cells, according to the literature 
(Palonpon et al., 2013). Briefly, 10 000 cells were seeded on a 25 x 25 x 1mm CaF2 coverslip 
in a cell culture dish (6 cm in diameter) containing DMEM and incubated for two days at 37° 
C in a humidified 5% CO2 atmosphere. AuNPs or 6AF-AuNPs were added to FBS-free 
DMEM (to a final concentration of 0.45 - 5.0 x 108 particles/mL) and incubated with cells 
overnight. The next day before SERS measurements, cells were rinsed three times with HBTS 
to remove excess of nanoparticles in the medium. Typical cell medium containing phenol red, 
has fluorescence that hinders the Raman signals. In addition, various types of biomolecules in 
the serum can be a source of possible background signal for SERS mapping. Thus, during 
SERS mapping, the cell culture medium was replaced with HBTS. Two control experiments 
were carried out to exclude auto fluorescence of cells and to exclude the contribution of 
normal Raman signal of the dye non-conjugated to AuNPs.  
 
Antioxidant screening 
For antioxidant screening experiment, Cyanidin 3-glucoside (C3G) was always freshly 
dissolved in DMSO and used immediately. The final concentration of DMSO in the culture 
medium during different treatments was <0.1% (v/v). Sub-confluent cells were treated for 1 h 
in serum-free medium with 25 µM of C3G, whereas all control cells were treated with 0.1% 
DMSO only. After this incubation time, cells were washed three times with HBTS under 
sterile conditions, to avoid the presence of C3G during SERS measurements. Cells were then 
incubated for 30 minutes with 5 mM 2,2′-Azobis(2-methylpropionamidine) dihydrochloride 
(ABAP) dissolved in HBTS to induce oxidative stress. ABAP is a commonly used azo 
initiator that can initiate both free radical and nucleophilic oxidations (Werber et al., 2011). 
At the end of the exposition, cells have been immediately processed for SERS mapping 
measurements.  
 
Data Processing 
All data preprocessing and analysis was performed within the R software environment for 
statistical computing and graphics (The R Core Team, 2014) and in-house written scripts. In 
particular, data import and export, preprocessing and visualization were performed with the 
hyperSpec package (Beleites & Sergo, 2014) for R, along with the lattice (Cheshire, 2010), 
and ggplot2 package (Ginestet, 2011) for graphical display.  
 
Data acquisition, conversion, and storage 
The preprocessing consisted of four steps: i) cosmic rays identification and removal, ii) 
baseline correction iii) smoothing interpolation, and iv) intensity vector-normalization. For 
the baseline correction, a linear baseline was fit automatically to the whole spectral range and 
was subtracted from each spectrum of the dataset using function modpolyfit from package 
baseline (Hovde Liland & BjÃ, 2015), and peak picking was performed using detectPeaks 
from package MALDIquant (Gibb & Strimmer, 2012). Each spectrum was normalized to its 
mean spectral intensity across all wavenumbers in order to account for fluctuations in laser 
intensity. 
 
Statistical analysis 
After preprocessing, the spectral contribution of cellular background was subtracted applying 
a cutoff threshold to intensity of single peaks. All the pixels with intensity i below this cutoff 
were set to zero. Next, a mean spectrum was generated by taking the arithmetic mean of the 
processed spectra. In addition to univariate testing, multivariate statistical methods were 
adopted for data interpretation. High dimensionality is one of the major obstacles to statistical 
analysis of spectroscopic data. PCA was performed on the mean spectra derived from the four 
groups of treatment. 
Results and discussion 
 
Nanoparticle Tracking Analysis (NTA) 
Distributions of the hydrodynamic diameters of the 6AF-AuNPs in the different samples were 
measured by the NTA method. This technique efficiently measures the velocity of tiny 
particles within the fluid streams moving at the velocity of the fluid. NTA allows 
nanoparticles to be sized in suspension on a particle-by-particle basis, with higher resolution 
and therefore better understanding of aggregation than other methods such as dynamic light 
scattering (DLS) and differential centrifugation sedimentation (DCS) (Montes-Burgos et al., 
2009). 
Table 1 shows the average diameter values and the concentration obtained by NTA for the 
citrate- and 6AF- capped AuNPs samples in mQ H2O, and after centrifugation and re-
suspension in DMEM culture medium. All samples exhibit similar asymmetric distribution 
curves with slow decaying tails towards large particle diameters, but with different 
distribution widths (Figure 1). The pH of the DMEM culture medium at 37°C was 7.46 and. 
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Figure 7.2 Nanoparticles Tracking Analysis. A. Cit-NPs in mQ-water. B 6AF-NPs in mQ-water. C. Cit-NPs in 
DMEM. D. 6AF-NPs in DMEM 
In all instances, the pH of the culture medium decreased slightly when the particles were re-
suspended therein; however the observed decreases were not biologically significant. 
The NTA data demonstrates that the integrity of the 6AF-AuNPs suspended in cell culture 
medium was maintained as compared to the 6AF-NPs in water, with minimal signs of particle 
aggregation present.  
 
 
Table 7.1 The average diameters of the citrate-/ (Cit-AuNPs) and 6AF- (6AF-AuNPs) capped gold nanoparticles, 
obtained by nanoparticle-tracking analysis (NTA) measurements of the NPs samples in mQ water and in DMEM. 
 Average diameter 
(nm) ± SD 
Concentration 
(nps/mL) 
 mQ water DMEM mQ water DMEM 
Cit-AuNPs 43 ± 23 203 ± 94 8.56E8 2.85E8 
6AF-AuNPs 111 ± 40 112 ± 53 5.55E8 3.42E8 
 
 
Stability 
The stability of Au-NPs-size distribution was examined by repeating NTA measurements of 
the same samples after 1, 24, and 48 hours. In all these measurements, bimodal curves were 
obtained very similar to those obtained in the first measurement carried out right after the 
AuNPs were generated. 
 
Cytotoxicity and cellular uptake 
To evaluate the cytotoxicity of the nanosensor, an AlamarBlue assay in Human endothelial-
like immortalized cells (EA.hy926) was performed with nanosensor concentration in the 
range 2 nM - 200 µM (Figure 2). The viability of cells incubated with 6Af-AuNPs for up to 3 
days was tested and compared with cells left untreated. According to the experimental 
observations, the cell viabilities were all more than 90% compared to the control experiments. 
  
 
 
 
 
 
 
 
 
 
 
 
TEM (Figure 3) confirmed that, when 6Af-NS were taken up by the cells of all of four cell 
lines in serum-free DMEM growth media. It should be noted that the 6AF-AuNPs were 
predominantly in the cytoplasm and neither encapsulated in vesicles nor coated in lipids. We 
could observe aggregates of nanoparticles inside cells, which appear as dark spots of the same 
dimension (~100 nm) measured by NTA. Since no sign of aggregation of AuNPs have been 
observed in the cell culture medium, therefore we concluded that aggregation was induced 
inside the endocytotic compartments.  
1μm
Figure 7.3 AlamaBlue assay of human EA.hy926 cells in the presence of different 
concentrations of the nanosensor (n=6). 
Figure 7.4 TEM images of 6AF–NPs in RAW cells. 
While the exact mechanism of uptake remains a matter of investigation, these findings are in 
agreement with previous studies of nanoparticle uptake which found that nanoparticles can 
enter cells through a variety of pathways resulting in accumulation in the cytoplasm and may 
be linked to physical factors such as electrostatics or van der Waals forces (Geiser et al., 
2005; Rosi et al., 2006; Rothen-Rutishauser et al., 2007; Schaeublin et al., 2011). 
 
Intracellular Surface-Enhanced Raman Spectroscopy with 6AF-AuNPs 
The NSs used in this study were designed to be excited with lasers in the near-infrared region 
(see previous chapter for details), which has excellent transmittance through tissue. To 
investigate the potential chemical information gathered from the molecular vibrations of 
biomolecules, we performed SERS mapping for SH-SY5Y cells incubated with 6AF-AuNPs. 
The control groups were the cell cultures incubated in label-free medium and medium 
containing 6AF. For both groups, no Raman signal was recorded (data not shown). According 
to previously reported results, the use of 735-nm laser excitation and short integration time 
(0.3 s) does not provide intracellular chemical information without SERS support. SERS 
cellular mapping measurements provided a spectrum for every pixel interrogated within a 
single cell (Sathuluri et al., 2011). 
The intensity of single peaks or peak regions assigned to a particular molecular vibration(s) 
within a field of interest were used to generate pseudo-color images showing the spatial 
distribution of chemical species within the cell (Figure 4). Similar to what has been reported 
by Salvati (Salvati et al., 2011) and Jaworska (Jaworska et al., 2015), after the uptake of 
nanoparticles containing high concentrations of a labile dye, the dye molecules are randomly 
spread across the intracellular space, whereas the dye conjugated to nanoparticles is spatially 
localized. 
 
 
 
 
Intracellular measurements are affected by the length of time required for cellular NS uptake 
before SERS mapping. The SERS bands of 6AF were observed in the spectra recorded for 
incubation times up to 48 h. Their cellular distributions in the cluster maps implicate a 
decrease in the concentration of 6AF-AuNP particles after a long incubation time (48 h). 
However, because the SERS spectra for each incubation time also show the presence of bands 
attributed to various biomolecules, we hypothesized that a detachment of the 6AF molecules 
from the enhancing surface of the gold occurred in favor of other biomolecules in close 
vicinity to hot spots. 
In preliminary studies probing 6AF-AuNP response in Eahy926 cells, we observed the SERS 
signal of the dye after only 3 h of incubation, whereas SERS bands originating from various 
biomolecules were observed up to 16 h. This result indicates that the conjugation of 6AF to 
nanoparticles is stable in the cellular environment up to a few hours.  
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Figure 7.5 SERS mean spectra extracted from cluster maps of SH-SY5Y cells incubated with 6AF-AuNPs (A); 
stressed with ABAP (D); in the presence (B) or not (C) of pre-treament with C3G, along with a microphotography of 
a cell and a total intensity maps before pre-processing. 
 
Assays of oxidative stress 
SERS mapping generates large and complex datasets, thus creating the need for adequate data 
reduction and analysis. PCA is a suitable tool for these data manipulations, and it also 
facilitates sample group discrimination in SERS mapping (Llabjani et al., 2011; Martin et al., 
2010). The authors suggested that the number of spectra should be several times greater than 
the number of variables/features in the dataset. Because the number of spectra (n = 4112) for 
each map was almost five times the number of variables (865 data points), we applied PCA. 
PCA generates loadings and score plots from the derived PCs of the initial or preprocessed 
data. The obtained PC loadings are correlation coefficients between the original data and PC 
scores. PC loadings identify the importance of each variable (i.e., peak in a SERS spectrum). 
The correlation of a variable to a PC reflects its contribution to the variation in the dataset. 
Therefore, plots of PC loadings reveal vibrational modes (wavenumbers) corresponding to the 
variation, which allows for distinction between groups. Thus, we applied PCA to our 
hyperspectral data to fulfill two aims: data reduction to fewer dimensions and objective 
distinction between cell groups (control cells [ctrl], stressed with ABAP with [test] or without 
[stress] protective C3G pre-treatment [c3g]).  
PCA was performed on a data matrix containing 173 mean SERS spectra, which were 
collected from the four treatment groups (ctrl = 38; stress = 59; c3g = 38; test = 38). To allow 
for group classification, we applied PCA to mean-centered, vector-normalized individual 
datasets, and the first and second PC scores were plotted with data point coloration according 
to cell groups (Figure 5). To obtain the PC scores plot, we analyzed SERS spectra belonging 
to all cells without providing information about treatment type. Thus, any observed clustering 
of the spectra was considered unbiased and indicative of a common underlying biochemical 
signature for the particular treatment. 
 
 Conclusions 
SERS-based imaging techniques applied to small molecules complement the growing 
research field of single-cell metabolomics and can be used to interpret many key biological 
processes in cells. The results of this study suggest that our approach using 6AF-AuNPs and 
SERS mapping could contribute greatly to the future characterization of antioxidant activity 
in biomedical and food research. We showed that 6AF-AuNPs can be internalized by cells 
and have little or no cytotoxicity even at high probe concentrations (above micromolar 
levels). These versatile and simple ROS/RNS detection probes and assay platforms can be 
used to relate ROS/RNS detection with oxidative stress status in living cells. 
Translating this proof of principle to clinical utility requires further studies, however. The 
next step must be the characterization of the cellular fingerprint for a biochemical 
interpretation of each SERS spectrum. Furthermore, combining multiple statistical analysis 
techniques with SERS mapping into an integrated platform would be a large step forward in 
the simultaneous measurement of intracellular ROS-generating events.  
Figure 7.6 PCA scores plot of mean spectra showing the interclass variance. To obtain this scores plot, each cell in 
the dataset is treated as a class without specifying the four classes (i.e., control, pretreated with C3G, stressed with 
ABAP in presence or absence of C3G treatment). After PCA, individual cells’ spectra were given a matching color in 
accordance with their original group types. 
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Section IV - Conclusions & future 
directions
Targeting natural antioxidant compounds to the brain 
 
There is currently spare evidence in literature describing the mechanistic relationship between 
dietary flavonoids, such as cyanidin 3-glucoside, and improved cognitive function. With this 
thesis, we have successfully conducted a multilevel integrated study that set the 
pharmacokinetic conditions to succeed in observing neuroprotective and cognitive 
enhancement activities in future in vitro and in vivo experiments. Furthermore, these 
conditions are important when designing and interpreting intervention trials in animals and 
humans, aimed at establishing the link between intake of anthocyanin-rich food/nutraceuticals 
and protection against age-related cognitive dysfunctions. 
The data presented here could also be useful for awarding the rationale for using the 
flavonoid-rich diet and/or the pure dietary flavonoids as nutraceuticals to enhance 
neuroprotective pathways in healthy population. This preventive approach could be further 
incorporated into the interventions strategies to prevent oxidative stress-induced diseases. 
Ultimately, experiments will have an impact on society by contributing new knowledge in 
designing the recommended dietary guidelines for healthy brain aging. 
Future Direction 
Given the heterogeneity of almost all biological systems, and the limitations of big untargeted 
experiments, it is evident here that there’s a need for improved methods for measuring 
metabolomics in single cells, preferably noninvasively and in vivo.  
Findings from SERS mapping will be implemented in the creation of an experimental model 
that simulates astrocyte metabolic dysfunction, mimicking the pathological mechanisms 
occurring in neurodegenerative disorders, in particular Parkinson’s and Alzheimer’s disease. 
Such model should find applications in basic studies but could also be exported to applied 
research, for example, when considering the cellular responses to New Chemical Entities. 
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